EHA / 14th Congress / Program overview per day / Saturday Program
Poster Session II
POSTER-WALKS
We would like to invite you to the EHA Poster sessions
Poster walks have been introduced in order to gain a maximum benefit from the scientific work presented and to create a lively interaction and discussion between poster authors, moderators and interested delegates. Poster-walks will be organized during poster sessions on Friday, June 5 (17:45 – 19:00) and Saturday, June 6 (18:00 – 19:15). The poster area is located in Hall 12 and Hall 14.1. Poster-walk moderators can be recognized by their cap. We kindly ask you to be in time at the first poster in the poster session of your interest. Drinks and snacks will be served.
POSTER SESSION IIPoster presentation during Poster-walks from 18:00 – 19:15. Poster Area (Hall 12 and Hall 14.1)
- GROWTH FACTORS, RECEPTORS AND SIGNALING
Poster-walk Moderator: S Constantinescu (Ludwig Institute for Cancer Research, Brussels, Belgium) - DRUG RESISTANCE AND PHARMACOLOGY
Poster-walk Moderator: P Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands) - ANEMIA, APLASTIC ANEMIA - PNH
Poster-walk Moderator: A Taher (American University of Beirut Medical Center, Achrafieh, Lebanon) - GRANULOCYTES
Poster-walk Moderator: I Touw (Erasmus Medical Center, Rotterdam, The Netherlands) - ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY
Poster-walk Moderator: G Martinelli (Istituto Europeo di Oncologia, Milan, Italy) - CHRONIC MYELOID LEUKEMIA - CLINICAL
Poster-walk Moderator: A Hochhaus (Medizinische Universitätsklinik, Mannheim, Germany) - MYELOPROLIFERATIVE DISORDERS - CLINICAL
Poster-walk Moderator: A Reiter (Medizinische Universitätsklinik, Mannheim, Germany) - NON-HODGKIN LYMPHOMA - BIOLOGY
Poster-walk Moderator: G Gaidano (Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy) - TRANSFUSION MEDICINE
Poster-walk Moderator: J A Moulds (LifeShare Blood Centers, Shreveport, USA) - STEM CELL TRANSPLANTATION – DISEASE RELATED
Poster-walk Moderator: A Gratwohl (University Hospital, Basel, Switzerland) - STEM CELL TRANSPLANTATION – MISCELLANEOUS
Poster-walk Moderator: H Greinix (Allgemeines Krankenhaus, Vienna, Austria) - NOVEL THERAPEUTICS, TARGETED THERAPIES AND GENE THERAPY - PRECLINICAL
Poster-walk Moderator: K Ozawa (Jichi Medical University, Shimotsuke-Shi, Japan) - RED BLOOD CELLS AND IRON III
Poster-walk Moderator: J Porter (University College, London, United Kingdom) - PLATELETS AND THROMBOCYTOPENIA II
Poster-walk Moderator: C Balduini (IRCCS San Matteo-University, Pavia, Italy) - MYELODYSPLASTIC SYNDROMES II
Poster-walk Moderator: W-K Hofmann (Unversity Hospital, Mannheim, Germany) - ACUTE MYELOID LEUKEMIA - BIOLOGY III
Poster-walk Moderator: G Martinelli (Institute of Hematology "Seràgnoli", Bologna, Italy) - ACUTE MYELOID LEUKEMIA – CLINICAL II
Poster-walk Moderator: B Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands) - CHRONIC MYELOID LEUKEMIA - BIOLOGY & CLINICAL
Poster-walk Moderator: J Goldman (Health Interactions, Atlanta, USA) - MYELOPROLIFERATIVE DISORDERS - BIOLOGY
Poster-walk Moderator: H Pahl (Center for Clinical Research, Freiburg, Germany) - MYELOPROLIFERATIVE DISORDERS - BIOLOGY & CLINICAL
Poster-walk Moderator: T Green (University of Cambridge, Cambridge, United Kingdom) - CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY II
Poster-walk Moderator: P Ghia (Università Vita-Salute San Raffaele, Milan, Italy) - CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL II
Poster-walk Moderator: T Robak (Medical University, Lodz, Poland) - MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY II
Poster-walk Moderator: E Terpos (251 General Airforce Hospital, Athens, Greece) - MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL II
Poster-walk Moderator: J Bladé (Hospital Clinic, Barcelona, Spain) - NON-HODGKIN LYMPHOMA - CLINICAL III
Poster-walk Moderator: G Salles (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) - NON-HODGKIN LYMPHOMA - CLINICAL IV
Poster-walk Moderator: M Dreyling (University of München-Großhadern, München, Germany) - THROMBOSIS AND VASCULAR BIOLOGY II
Poster-walk Moderator: P Mannucci (A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy) - INFECTIOUS DISEASES, SUPPORTIVE CARE II
Poster-walk Moderator: H Einsele (University Hospital, Würzburg, Germany)
GROWTH FACTORS, RECEPTORS AND SIGNALING
| 0556 | THE SOMATOSTATIN RECEPTOR 2 INDUCES A REVERSIBLE NEUTROPHILIC DIFFERENTIATION BLOCK |
|---|---|
| 0558 | SUSTAINED INCREASE OF CD69 ON ACTIVATED LYMPHOCYTES MEDIATED BY MESENCHYMAL STROMAL CELLS AND ITS POTENTIAL IMMUNOMODULATORY ROLE |
| 0559 | MACROPHAGES AS NOVEL TARGETS FOR ERYTHROPOIETIN |
| 0560 | MEMBRANE AND SOLUBLE CD40 LIGAND HAVE DIFFERENT EFFECTS ON BCL-6 EXPRESSION AND PRODUCE DIFFERENT PROTEIN/DNA COMPLEXES AT A SITE IN EXON 1 OF THE BCL-6 GENE |
| 0561 | ALTERNATIVE USE OF EXON 1 AND DIFFERENTIAL REGULATION OF EXPRESSION OF DOCK10 ISOFORMS BY INTERLEUKIN-4 A. Parrado, M.J. Alcaraz-García, M.V. Bernardo, M.J. Majado (Hospital Virgen de la Arrixaca, Murcia, Spain) |
| 0562 | BIOEQUIVALENCE OF A NEW BIOSIMILAR FILGRASTIM AND NEUPOGEN: PHARMACOKINETIC, PHARMACODYNAMIC AND SAFETY DATA FROM TWO RANDOMISED, PHASE I, HEALTHYVOLUNTEER STUDIES C.F. Waller, M.H. Bronchud, S.J. Mair (Freiburg University Medical Center, Freiburg, Germany) |
| 0563 | AKT AND PKC AS REGULATORS OF DIFFERENTIATION AND TELOMERASE ACTIVITY IN LEUKEMIC CELLS O. Yamada, K. Ozaki, M. Nakadake, M. Akiyama, K. Kawauchi, R. Matsuoka (Tokyo Women's Medical University, Tokyo, Japan) |
| 0564 | A PHASE II RANDOMIZED STUDY COMPARING PEGFILGRASTIM (PEG) VS FILGRASTIM (FIL) AFTER HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL SUPPORT (PBSC) L. Castagna, S. Bramanti, A. Levis, M.G. Michieli, A. Anastasia, B. Sarina, L. Giordano, E. Todisco, R. Mazza, A. Santoro (Istituto Clinico Humanitas, Rozzano (Milan), Italy) |
| 0565 | COMPARATIVE EFFECT OF FILGRASTIM VS. PEGFILGRASTIM AFTER CHEMOTHERAPY ON HIGH GRADE NON HODGKIN LYMPHOMA E. Magro Mazo, J.J. Gil-Fernandez, J. Garcia Suarez, M. Callejas Charavia, Y. Martin Guerrero, T. Pascual Garcia, M. Lopez-Rubio (Hospital Príncipe de Asturias, Madrid, Spain) |
| 0566 | AN ERYTHROPOIETIN AND CYCLOPHOSPHAMIDE COMBINATION ADDITIVELY ENHANCES IMMUNOGLOBULIN PRODUCTION IN MICE A. Berger, L. Lifshitz, M. Mittelman, D. Neumann (Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel) |
| 0567 | ATYPICAL WHIM SYNDROME ASSOCIATED WITH GRANULOMATOSIS: REPORT OF TWO CASES A.-V. Doncker, K. Balabanian, C. Bellanne-Chantelot, S. de Guibert, F. Bachelerie, T. Lamy (Pontchaillou Hospital, Rennes, France) |
| 0568 | THE PHYSICOCHEMICAL PROPERTIES OF A BIOSIMILAR FILGRASTIM ARE COMPARABLE TO THOSE OF NEUPOGEN A. Skrlin, I. Radic, M. Vuletic, D. Schwinke, D. Runac (PLIVA Croatia Ltd, Zagreb, Croatia) |
DRUG RESISTANCE AND PHARMACOLOGY
| 0569 | THE PROTEASOME INHIBITOR BORTEZOMIB MODULATES THE EFFECT OF GLUCOCORTICOID TREATMENT IN PREDNISONERESISTANT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA CELLS |
|---|---|
| 0570 | IMATINIB INDUCES AUTOPHAGY THROUGH INCREASING THE EXPRESSION LEVELS OF BECLIN-1 AND ATG-5 GENES IN BOTH PARENTAL SENSITIVE AND IMATINIB-RESISTANT K562 CELLS |
| 0571 | DEVELOPMENT OF A PERSONALIZED MEDICINE TEST FOR HAEMATOLOGICAL MALIGNANCIES |
| 0572 | EFFECTS OF THALIDOMIDE, ROFECOXIB AND CAPTOPRIL ON VASCULAR ENDOTHELIAL GROWTH FACTOR IN EHRLICH ASCITES CARCINOMA |
| 0573 | A VERY SENSITIVE AND RAPID METHOD FOR BCR-ABL T315I MUTATION DETECTION BY PEPTIDE NUCLEIC ACID DIRECTED PCR CLAMPING E. Bracco, M. Spagna, R. Pedrola, V. Rosso, F. Arruga, M. Lo Iacono, S. Carturan, F. Messa, C. Panuzzo, P. Nicoli, E. Messa, A. Rotolo, A. Morotti, S. Mussino, A. Balbo, D. Cilloni, S.G. Saglio (University of Turin, Orbassano, Italy) |
| 0574 | DEVELOPMENT OF A NOVEL METHOD TO EVALUATE THEEFFICACY OF MOLECULAR TARGETED THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA BY BIO-IMAGING SYSTEM T. Kondo, T. Mizutani, S. Darmanin, M. Tsuda, J. Tanaka, M. Imamura, H.K. Kawaguchi, M.A. Asaka, Y.O. Ohba (Hokkaido University Graduate School of Medicine, Sapporo, Japan) |
| 0575 | MULTIDRUG RESISTANCE TESTING WITH ABC TRANSPORTER ASSAY K. Tauber Jakab, J. Marki-Zay, E. Kis, K. Herédi-Szabó, Z. Hollo, P. Krajcsi (Solvo Biotechnology, Budaörs, Hungary) |
| 0576 | ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN DE NOVO AML WITH NORMAL KARYOTYPE - IMPLICATIONS ON DRUG RESISTANCE AND SURVIVAL E. Paul, K. Lotfi, I. Jakobsen Falk, R. Rosenquist, C. Paul, H Nahi, H. Green (Karolinska Institutet, Huddinge, Sweden) |
| 0577 | ANALYSIS, PHARMACOKINETICS AND BIODISTRIBUTION OF THE NEW CDK INHIBITOR-CR8 H. Sallam, L. Meijer, M. Hassan (Karolinska Institutet, STOCKHOLM, Sweden) |
| 0578 | EXPRESSION OF PHOSPHORYLATED HISTONE H2AX AND ITS POTENTIAL TO MODULATE ADRIAMYCIN RESISTANCE IN K562/A02 CELL LINE F. Zhou, H. Mei, Q. Wu, R. Jin (Huazhong University of Science & Technology, Wuhan, China) |
ANEMIA, APLASTIC ANEMIA - PNH
| 0579 | GENETIC ANALYSIS OF THE SHELTERIN COMPLEX COMPONENTS (POT, RAP, TPP, TRF1 AND TRF2) IN DYSKERATOSIS CONGENITA |
|---|---|
| 0580 | IMMUNOSUPPRESSIVE THERAPY WITH RABBIT ANTITHYMOCYTE GLOBULIN (R-ATG) MIGHT BE COMPARABLE TO HORSE ANTILYMPHOCYTE GLOBULIN (H-AG) IN CHILDHOOD SEVERE APLASTIC ANEMIA WITHOUT HLA-IDENTICAL SIBLING DONOR |
| 0581 | EFFICACY OF THE COMPLEMENT INHIBITOR ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS NEVER TRANSFUSED |
| 0582 | HOME INFUSION OF ECULIZUMAB: A UNIQUE AND INNOVATIVE MODEL OF DRUG DELIVERY TO REDUCE TREATMENT-ASSOCIATED BURDEN AND ENHANCE QUALITY OF LIFE FOR PATIENTS WITH PNH |
| 0583 | USE OF FLAER-BASED ASSAY OF WHITE BLOOD CELLS (MONOCYTES AND GRANULOCYTES) IN THE PRIMARY SCREENING OF PNH CLONES D.R. Sutherland, M. Keeney, N. Kuek, J. Azcona-Olivera, E. Acton, T. Anderson, D. Barth, M. Reis (Toronto General Hospital, Toronto, Canada) |
| 0584 | EFFECT OF ECULIZIMAB THERAPY ON THROMBOCYTOPENIA IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) I. Weitz, L. Rochanda, H. Liebman (University of Southern California, Los Angeles, USA) |
| 0585 | EFFICACY OF THE TERMINAL COMPLEMENT INHIBITOR ECULIZUMAB USED CHRONICALLY IN A PATIENT WITH COLD AGGLUTININ DISEASE (CAD) A. Röth, A. Hüttmann, C. Hock, R. Rother, U. Dührsen, T. Philipp (University Hospital Essen, Essen, Germany) |
| 0586 | ANEMIA DURING PEGYLATED INTERFERON-RIBAVIRIN THERAPY RESULTS FROM BOTH INCREASE SUPPRESSION OFERYTHROID DIFFERENTIATION AND HEMOLYSIS L. Ronzoni, A. Aghemo, M.G. Rumi, A. Colancecco, S. Monico, P. Grillo, M. Colombo, M.D. Cappellini (Fondazione Policlinico, Mangiagalli, Regina Elena IRCCS, University of Milan, Milan, Italy) |
| 0587 | MODIFICATION OF THE STANDARD ECULIZUMAB DOSE TO SUCCESSFULLY MANAGE INTRAVASCULAR HAEMOLYSIS BREAKTHROUGH IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA R.J. Kelly, L.M. Arnold, S.J. Richards, A. Hill, S. van Bijnen, P. Muus, D. Dorr, R. Brodsky, J. Beauchamp, G. Khursigara, R.P. Rother, P. Hillmen (St James's University Hospital, Leeds, United Kingdom) |
| 0588 | DIAGNOSING IRON DEFICIENCY ANEMIA IN PATIENTS WITH RHEUMATOID ARTHRITIS E.C. van Dongen-Lases, A.M. Linssen, F. de Vegt, P.L.C.M. van Riel, D.W. Swinkels, A.E. van Ede (UMC St. Radboud, Nijmegen, The Netherlands) |
| 0589 | IN VITRO EFFECT OF RIBAVIRIN AND PEGYLATED INTERFERON ON ERYTHROPOIESIS L. Ronzoni, A. Colancecco, A. Cattaneo, A. Aghemo, M.G. Rumi, M. Colombo, M.D. Cappellini (Fondazione Policlinico, Mangiagalli, Regina Elena IRCCS, University of Milan, Milan, Italy) |
| 0591 | LONG-TERM OUTCOME OF ACQUIRED APLASTIC ANEMIA: COMPARATION BETWEEN IMMUNOSUPPRESSIVE THERAPY AND BONE MARROW TRANSPLANTATION Lj. Tukic, D. Stamatovic, O. Tarabar, M. Elez, Z. Tatomirovic, O. Radic-Tasic, B. Balint, N. Kuljic-Kapulica (Military Medical Academy, Belgrade, Serbia) |
| 0592 | THALASSEMIA INTERMEDIA: AN EGYPTIAN EXPERIENCE G. Mokhtar, A. A.G.Tantawy, A. A.Abdel Moneim, M. Waheed (Faculty of Medicine, Ain Shams University, Cairo, Egypt) |
| 0593 | SUCCESSFUL TREATMENT OF COMPLEMENT MEDIATEDREFRACTORY HAEMOLYSIS ASSOCIATED WITH COLD AND WARM AUTOANTIBODIES USING ECULIZUMAB M. Bommer, B. Höchsmann, W.A. Flegel, H. Doehner, H. Schrezenmeier (University of Ulm, Ulm, Germany) |
| 0594 | EFFECT OF DIHYDROARTEMISININ (DHA) ON HUMAN ERYTHROID CELL DIFFERENTIATION: IMPLICATIONS FOR MALARIA TREATMENT IN PREGNANCY S. Finaurini, L. Ronzoni, A. Colancecco, M.D. Cappellini, D. Taramelli (University of Milan, Milan, Italy) |
| 0595 | OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF THE NF-KB LIGAND (RANKL) IN EGYPTIAN PATIENTS WITH THALASSEMIAINDUCED OSTEOPOROSIS A.E.D.S. Abd El Hamid, M. Attia, A. Saad, M. El Nesr, M. Hassan Saleh (Faculty of Medicine, Suez Canal University, Ismailia, Egypt) |
| 0596 | A CHILD WITH DYSKERATOSIS CONGENITA AND RECENTLY DESCRIBED TINF2 MUTATION N. Sarper, E. Zengin (Kocaeli University, Kocaeli, Turkey) |
| 0597 | HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADOLESCENTS AND ADULTS. UNDERESTIMATED PROBLEM? W. Jedrzejczak, M. Jablonska, E. Dwilewicz-Trojaczek, G. Ziarkiewicz- Wroblewska, J. Dzieciatkowski, P. Boguradzki, R. Charlinski, M. Wiater, J. Witkowska, T. Waszczuk-Gajda, W. Hensler, M. Tormanowska (Medical University of Warsaw, Warsaw, Poland) |
| 0598 | TAFI (THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR) AS A MARKER OF HEMOSTATIC ALTERATION IN PATIENTS WITH BETATHALASSEMIA R.M. Matter, G.M. Mokhtar, M.M. Abdel Aziz, H.S. Mortagi (Ain Shams University, Cairo, Egypt) |
GRANULOCYTES
| 0599 | NAMPT IS ESSENTIAL FOR THE G-CSF-INDUCED MYELOID DIFFERENTIATION |
|---|---|
| 0600 | REGULATION OF GRANULOPOIESIS BY NAMPT / NAD+ / SIRT1 DEPENDENT ACTIVATION OF C/EBP_ IN PATIENTS SUFFERING FROM SEVERE CONGENITAL NEUTROPENIA (CN) |
| 0601 | IS THE RISK OF DEVELOPING AML OR MDS INCREASED IN X-LINKED NEUTROPENIA |
| 0602 | STUDY OF THE QUANTITATIVE AND FUNCTIONAL CHARACTERISTICS OF T REGULATORY CELLS IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA |
| 0603 | ABNORMALITIES OF SERUM IMMUNOGLOBULIN LEVELS IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA: RESULTS FROM A COHORT OF 295 PATIENTS I. Mavroudi, V. Papadaki, K. Pyrovolaki, M. Velegraki, M. Spanoudakis, M. Kaparou, P. Kanellou, G. Gvazava, G.D. Eliopoulos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece) |
| 0604 | NOVEL G6PC3 MUTATIONS IDENTIFIED IN AUTOSOMAL RECESSIVE SCN PATIENTS WITH AND WITHOUT CONGENITAL ABNORMALITIES N. Smith, B. Hayee, C. Evans, P. Ancliff, G. Hall, A. Segal, D. Linch, R. Gale (UCL Cancer Institute, University College London, London, United Kingdom) |
| 0605 | DIFERENTIAL STIMULATION OF MONOCYTIC CELLS RESULTS IN DISTINCT POPULATIONS OF MICROPARTICLES M.P. Bernimoulin, E.K. Waters, M. Foy, B.M. Steele, M. Sullivan, H. Falet, M.T. Walsh, N. Barteneva, J.-G. Geng, J.H. Hartwig, P.B. Maguire, D.D. Wagner (Hopital Necker, Paris, France) |
| 0606 | LEUKOPENIA AND WAS GENE MUTATION IN AN INFANT. A CASE REPORT A. Catala, S. Rives, T. Toll, M. Camos, R. Berrueco, N. Conde, A. Quintero, J.I. Arostegui, J. Estella (Hospital Sant Joan de Deu, Barcelona, Spain) |
| 0607 | GLUCOCORTICOIDS REVERT THE DASATINIB-MEDIATED ENHANCEMENT OF HISTAMINE RELEASE IN IGE-R CROSSLINKED BASOPHILS H. Herrmann, K. Blatt, M. Klauser, M. Kneidinger, K. Marth, R. Valenta, P. Valent (Medical University of Vienna, Vienna, Austria) |
| 0608 | CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF LANGERHANS CELL HISTIOCYTOSIS: LARGE STUDY OF SINGLE INSTITUTE H.J. Kang, J.W. Lee, H. Kim, H.Y. Shin, H.S. Ahn (Seoul National University College of Medicine, Seoul, South-Korea) |
ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY
| 0609 | NK-LIKE HOMEODOMAIN PROTEINS ACTIVATE NOTCH3- SIGNALING IN LEUKEMIC T-CELLS |
|---|---|
| 0610 | PROGNOSTIC SUBGROUPS DEFINED IN A NOD/SCID/HUALLXENOGRAFT MODEL FOR PAEDIATRIC B CELL PRECURSOR ALL ARE CHARACTERISED BY A GENE SIGNATURE INVOLVING SURVIVAL PATHWAYS AND IDENTIFY POTENTIAL NEW THERAPEUTIC TARGETS |
| 0611 | APOPTOSIS DEFICIENCY DEFINES PROGNOSTIC SUBGROUPS AND THERAPY RESISTANCE IN A XENOGRAFT MODEL OF PEDIATRIC BCP- ALL |
| 0612 | METHADONE IMPROVES THERAPEUTIC SUCCESS IN LEUKEMIA CELLS IN VITRO AND EX VIVO |
| 0613 | PERIPHERAL BLOOD INVOLVEMENT PROVIDES AN IMPORTANT PROGNOSTIC INFORMATION DURING EARLY TIME POINTS OF CHILDHOOD ALL TREATMENT J. Volejnikova, E. Fronkova, E. Mejstrikova, K. Muzikova, L. Reznickova, D. Pospisilova, V. Mihal, J. Sterba, Y. Jabali, D. Prochazkova, B. Blazek, J. Hak, Z. Cerna, J. Stary, J. Trka (2nd Medical School, Charles University Prague, Prague, Czech Republic) |
| 0614 | AID EXPRESSION IN BCR/ABL POSITIVE ALL IS ASSOCIATED WITH A PECULIAR GENE EXPRESSION PROFILE AND DEREGULATION OF DNA REPAIR AND REPLICATION GENES M. Messina, S. Chiaretti, I. Iacobucci, S. Tavolaro, A. Vitale, I. Della Starza, A. Lonetti, C. Papayannidis, A.D. Negulici, S. Soverini, D. Cilloni, A. Guarini, G. Martinelli, R. Foà (Sapienza University, Rome, Italy) |
| 0615 | THE IMMUNOMODULATORY AGENT FTY720 INDUCES APOPTOSIS AND INHIBITS GROWTH OF BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND OVERCOMES IMATINIB RESISTANCE IN VITRO A. Schmidt-Tanguy, S. Badura, B.A. Nijmeijer, S. Wystub, A. Romanski, O.G. Ottmann (University, Frankfurt, Germany) |
| 0616 | PROGNOSTIC INTEREST OF BIPARAMETRIC CD45-DNA ANALYSIS OF MEDULLAR LYMPHOBLASTS AT DIAGNOSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA P. Rachieru-Sourisseau, E. De Carli, L. Baranger, F. Génèvieve,J. Rakotonjanahary, S. Proust, F. Mechinaud, N. Robillard, O. Minckes,V. Salaun, A. Robert, N. Dastugue, F. Millot, F. Brizard, A. Chassevent (C.H.U. Angers, Angers, France) |
| 0617 | ECTOPIC CDX2 EXPRESSION IS A FREQUENT AND PROGNOSTICALLY RELEVANT EVENT IN HUMAN ALL S. Thöne, V.P.S. Rawat, B. Heilmeier, E. Hoster, K. Metzeler, T. Herold, W. Hiddemann, N. Gökbuget, D. Hoelzer, S. Bohlander, M. Feuring-Buske, Ch. Buske (Helmholtz Zentrum München, Munich, Germany) |
| 0618 | MIRNA EXPRESSION PROFILE OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA EXPRESSING OR NOT CD56 H.L. Gimenes Teixeira, G.A. Dos Santos, P.S. Scheucher, D.L. Zanette, L.F. Dalmazzo, A.G. Araújo, W.A. Silva-Jr, R.P. Falcão (FMRP, Ribeiro Preto, Brazil) |
| 0620 | VALIDATION OF MX (MXA) AS A GENETIC MARKER FORGLUCOCORTICOID-INDUCED APOPTOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS? S. Junk, G. Cario, M. Lauten, N. Wittner, M. Schrappe, B. Schlegelberger, N. von Neuhoff (Hannover Medical School/ Institute of Cell and Molecular Pathology, Hannover, Germany) |
| 0621 | THE MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR RAD001 INHIBTS PROLIFERATION OF T- AND B-LYMPHOBLASTIC CELLS VIA CELL CYCLE ARREST C. Schult, F. Amoroso, M. Dahlhaus, S. Ruck, S. Lange, F. Buljubasic, M. Freund, L. Neri, C. Junghanss (University of Rostock, Rostock, Germany) |
| 0622 | IMMUNOPHENOTYPIC MODULATION IN ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSTIVE MRD AFTER INDUCTION TREATMENT P. Barba, A. Aventin, J. Úbeda, M. Carricondo, R. Martino, I. Badell, A. Parente, E. Bussaglia, C. Estivill, J. Sierra, J. Nomdedéu (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain) |
| 0623 | ONCOGENIC PIK3CA MUTATIONS ARE ABSENT IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) S. Wystub, H. Pfeifer, S. Badura, B. Nijmeijer, O.G. Ottmann (University of Frankfurt, Frankfurt, Germany) |
| 0624 | PROLIFERATIVE EFFECT OF HUMAN HEMOKININ-1 ON HUMAN PRE-B LYMPHOCYTE CELL LINE REH S. Grassin Delyle, E. Naline, A. Buenestado, L. Vallat, F. Remy, O.A. Bernard, P. Debré, C. Advenier, P. Devillier, H. Merle Béral (UPRES EA220, Suresnes, France) |
CHRONIC MYELOID LEUKEMIA - CLINICAL
| 0625 | THERAPY WITH IMATINIB IN ELDERLY CML PATIENTS (=65 YEARS) IS WELL TOLERATED BUT CYTOGENETIC AND MOLECULAR REMISSIONS SEEM TO BE ACHIEVED LATER COMPARED TO YOUNGER PATIENTS |
|---|---|
| 0626 | SOKAL SCORE AND RESPONSE TO IMATINIB IN EARLY CHRONIC PHASE CML: THE GIMEMA CML WORKING PARTY EXPERIENCE ON 559 PATIENTS |
| 0627 | NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY |
| 0628 | SUBOPTIMAL RESPONSE TO IMATINIB 400 MG DAILY FOR CHRONIC MYELOID LEUKEMIA IN EARLY CHRONIC PHASE: A GIMEMA CML WP ANALYSIS OF 423 CONSECUTIVE PATIENTS |
| 0629 | THE ORALLY ACTIVE AURORA KINASE A INHIBITOR MLN8237 HAS POTENT ACTIVITY IN PRECLINICAL MODELS OF RESISTANT CHRONIC MYELOID LEUKEMIA AND SIGNIFICANTLY INCREASES THE EFFICACY OF NILOTINIB R. Kelly, R. Swords, S. Nawrocki, D. Mahalingam, E. Medina, S. Smith, S. Padmanabhan, J. Ecsedy, F. Giles, J. Carew (Institute for Drug Development, San Antonio, USA) |
| 0630 | FINAL SAFETY ANALYSIS OF 1,793 CML PATIENTS FROM ENACT (EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) F.E. Nicolini, G. Alimena, H.K. Al-Ali, A.T. Turkina, Z. Shen, S. Jootar, G. Smith, C. De Souza, J. Wang, M. Berton, T. Szczudlo, D.A. Rizzieri (Hôpital Edouard Herriot, Lyon, France) |
| 0631 | NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY A. Hochhaus, F. Giles, J. Apperely, G. Ossenkoppele, J. Wang, N.J. Gallagher, M. Baccarani, J. Cortes, H. Kantarjian, P.D. Le Coutre (Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany) |
| 0632 | AGE HAS NO IMPACT ON OUTCOME OF EARLY CHRONIC PHASE, PH-POS CML, IMATINIB TREATED PATIENTS: A NATIONWIDE ANALYSIS ON 559 CASES OF THE GIMEMA CML WP G.G. Gugliotta, F. Castagnetti, M. Amabile, N. Testoni, F. Palandri, I. Iacobucci, S. Soverini, S. Luatti, M. Breccia, G. Specchia, T. Intermesoli, F. Radaelli, E. Abbruzzese, E. Usala, G. Saglio, G. Martinelli, F. Pane, M. Baccarani, G. Rosti (Dept. of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy) |
| 0633 | EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS (PTS) WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): SUBGROUP ANALYSIS OF PATIENTS WHO FAILED PRIOR DASATINIB THERAPY F.E. Nicolini, G. Alimena, H.K. Al-Ali, A.T. Turkina, Z. Shen, S. Jootar, G. Smith, M. Conchon, J. Wang, M. Berton, T. Szczudlo, D.A. Rizzieri (Hôpital Edouard Herriot, Lyon, France) |
| 0634 | RELEASE OF INTRACELLULAR CALCIUM PRIMES CHRONIC MYELOID LEUKAEMIA CELLS FOR TYROSINE KINASE INHIBITOR (TKI)-INDUCED APOPTOSIS S.L. Forchap, M. Pirmohamed, R.E. Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom) |
| 0635 | A SHORT (2M) IFNA/IMATINIB COMBINED THERAPY CAN SECURE LONG TERM MAINTENANCE OF IMATINIB INDUCED CYTOGENETIC REMISSION AFTER DISCONTINUATION OF IMATINIB IN CML PATIENTS WITHOUT MOLECULAR REMISSION I. Hardan, S.M. Stemmer, N. Amariglio, M. Koren-Michowitz, I. Levi, A. Shimoni, Y. Binenbaum, D. Ben-Yehuda, M. Bennett, G. Rechavi, A. Nagler (Sheba Medical Center, Tel-Hashomer, Israel) |
| 0636 | RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANTCHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E255K/V, Y253H, AND F359C/V G. Martinelli, D.W. Kim, G. Saglio, S. Branford, P. Erben, E. Gottardi, L. Beppu, A. Haque, Y. Shou, R. Woodman, S. Soverini, H. Kantarjian,T. Hughes, A. Hochhaus, J. Radich (Institute of Hematology and Medical Oncology, Bologna, Italy) |
| 0637 | A STUDY OF PLASMA LEVELS OF IMATINIB AND ITS BIOACTIVE METABOLITE CGP-74588 REVEALS NO CORRELATION WITH SUBSEQUENT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA A. Davies, A.K. Hayes, A. Giannoudis, C.M. Lucas, K. Knight, S.J. Watmough, M. Pirmohamed, R.E. Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom) |
| 0638 | DASATINIB IN THE TREATMENT OF CHRONIC PHASE CML PATIENTS AGED > 60 YEARS RESISTANT/INTOLERANT TO IMATINIB R. Latagliata, M. Breccia, F. Stagno, L. Luciano, A. Gozzini, M. Annunziata, S. De Matteis, F. Albano, S. Ulisciani, P. Pregno, M. Pacilli, E. Abruzzese, B. Martino, M. Tiribelli, A. Russo Rossi, S. Sica, U. Vitolo, E. Montefusco, G. Rege Cambrin, F. Ferrara, V. Santini, F. Pane, F. Di Raimondo, G. Alimena (Ematologia - Università “La Sapienza”, Rome, Italy) |
| 0639 | EFFICACY OF NILOTINIB AFTER IMATINIB FAILURE IN PH-POSITIVE CHRONIC MYELOID LEUKEMIA: IMPACT OF ADDITIONAL CHROMOSOMAL ABERRATIONS AND FREQUENCY OF BCR-ABL POINT MUTATIONS T.D.K. Kim, S. Türkmen, M. Schwarz, P. Daniel, B. Dörken, P. Le Coutre (Charité - Universitätsmedizin Berlin, Berlin, Germany) |
| 0640 | THE ONCOGENIC KINASE BCR-ABL DIRECTLY REGULATES SPLICING EVENTS OF BCLX THROUGH A QUATERNARY COMPLEX COORDINATED BY NCK-BETA AND SAM-68 ADAPTER PROTEINS E. Bracco, V. Rosso, S. Mussino, F. Arruga, S. Carturan, F. Messa, C. Panuzzo, M. Lo Iacono, P. Nicoli, E. Messa, A. Rotolo, M. Spagna, A. Morotti, A. Balbo, I.I. Iacobucci I., M.G. Martinelli, D. Cilloni, S.G. Saglio (University of Turin, Orbassano, Italy) |
| 0641 | COMPARATIVE IN VITRO CELLULAR DATA ALONE IS INSUFFICIENT TO GUIDE CHOICE OF BCR-ABL INHIBITOR TO TREAT IMATINIBRESISTANT CHRONIC MYELOID LEUKEMIA (CML) P. Laneuville, C. DiLea, J. Mestan, O. Yin, P.W. Manley (McGill University, quebec, Canada) |
| 0642 | DYNAMICS OF CYTOGENETIC AND MOLECULAR RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E255K/V, Y253H, AND F359C/V G. Saglio, A. Hochhaus, G. Martinelli, E. Gottardi, S. Soverini, S. Branford,M. Müller, L. Beppu, A. Haque, Y. Shou, R. Woodman, H. Kantarjian, J. Radich, T. Hughes, D.W. Kim (University of Turin San Luigi Gonzaga Hospital, Orbassano, Italy) |
| 0643 | LONG-TERM SURVIVAL OF PATIENTS WITH LATE CHRONIC PHASE PH-POSITIVE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITOR THERAPY AFTER INTERFERON FAILURE A.G. Turkina, O.V. Stakhina, G.A. Gusarova, E.S. Zakharova, E.Yu. Chelysheva, O.Yu. Vinogradova, T.I. Kolosheinova, C.R. Goryacheva, L.Yu. Kolosova, E.V. Domracheva, A.V. Zakharova, E.M. Abakumov, S.M. Kulikov, N.D. Khoroshko (Hematology Research Center, RAMS, Moscow, Russian Federation) |
| 0644 | PREGNANCY AMONG THE PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB THERAPY E.Y. Chelysheva, A.G. Turkina, G.A. Gusarova, T.I. Kolosheinova, M.A. Sokolova, N.D. Khoroshko, V.M. Pepelyaeva, L.V. Gavrilova (Hematology Research Center, Moscow, Russia, Moscow, Russian Federation) |
MYELOPROLIFERATIVE DISORDERS – CLINICAL
| 0645 | INCREASED RISK OF LYMPHOID MALIGNANCIES IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS |
|---|---|
| 0646 | THE LONG-TERM DURABILITY OF MOLECULAR RESPONSES IN PATIENTS WITH FIP1L1-PDGFRA CHRONIC HEOSINOPHILIC LEUKEMIA TREATED WITH IMATINIB: THE ITALIAN HES0203 EXPERIENCE AFTER A 4-YEAR FOLLOW-UP |
| 0647 | REDUCED SURVIVAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS IS PREDICTED BY A LOW BURDEN OF JAK2V617 MUTATED ALLELE |
| 0648 | POMALIDOMIDE IN MYELOFIBROSIS: RESULTS OF A PHASE-1 DOSE-SEEKING TRIAL |
| 0649 | PRIMARY AND SECONDARY RESISTANCE TO IMATINIB IS VERY RARE IN CHRONIC AND BLAST PHASE OF MYELOPROLIFERATIVE NEOPLASMS WITH REARRANGEMENTS OF PDGFRA AND PDGFRB G. Metzgeroth, P. Erben, C. Walz, D. Gosenca, J. Mix, C. Haferlach, S. Schnittger, N. C. P. Cross, A. Hochhaus, A. Reiter (III. Medizinische Klinik, Mannheim, Germany) |
| 0651 | THE EVALUATION OF XAGRID EFFICACY AND LONG-TERM SAFETY STUDY: MONITORING SAFETY OUTCOMES IN AT-RISK ESSENTIAL THROMBOCYTHAEMIA (ET) PATIENTS TREATED WITH ANAGRELIDE VS OTHER CYTOREDUCTIVE THERAPIES G. Birgegård, C. Besses, R. Coll, C. Freitag, M. Griesshammer, L. Gugliotta, C. Harrison, J.-J. Kiladjian (Uppsala University Hospital, Uppsala, Sweden |
| 0652 | LIVING WITH ESSENTIAL THROMBOCYTHEMIA IN FRANCE: PROSPECTIVE SURVEY ASSESSING DAILY LIFE DISEASE IMPACT IN 245 PATIENTS J. Rey, T. De Revel, P. Lenain, E. Raffoux, J.-J. Kiladjian (Paoli-Calmettes, Marseille, France) |
| 0653 | APLIDIN IMPROVES MEGAKARYOCYTOPOIESIS AND HALTS NEO-ANGIOGENESIS IN THE GATA1(LOW) MURINE MODEL OF MYELOFIBROSIS M. Verrucci, A. Pancrazzi, M. Paz, F. Martelli, P. Guglielmelli, M. Aracil, M. Zingariello, E. D'Amore, J. Jimeno, A.M. Vannucchi, A.R. Migliaccio (Istituto Superiore di Sanità, Rome, Italy) |
| 0654 | EFFICACY OF LENALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS: SPANISH COMPASSIONATE USE PROGRAM. PRELIMINARY ANALYSIS I. Castillo, A.M. Ojeda, C. Boqué, A. Asensio, M. Hermosilla, M. Blanes, J. Busto, V. Carrasco, I. Cuesta, A. Echeveste, C. Fernández-Miñano, P. García-Sánchez, J. Gil, F. Hernández, A. Ibañez, A. Lemes, A. Ramírez, D. Silvana, N. Somolinos, M.D. Monteagudo, C. Ulibarrena, D. Borrego (General Hospital of Elda, ELDA - Alicante, Spain) |
| 0655 | JAK2 V617F-POSITIVE CHRONIC EOSINOPHILIC LEUKEMIA: CLINICAL, LABORATORY AND MOLECULAR DEFINITION OF A DISTINCT DISEASE SUBTYPE K. Zoi, I.J. Dahabreh, C. Zoi, G. Helbig, S. Krzemien, V. Gota, M. Speletas, S. Giannouli, A. Palliou, K. Stefanoudaki, N. Harhalakis, G. Vassilopoulos, M. Kotsopoulou, P. Tsirigotis, H.M. Moutsopoulos, D. Loukopoulos, M. Voulgarelis (Biomedical Research Foundation, Academy of Athens, Athens, Greece) |
| 0656 | UK SYSTEMIC MASTOCYTOSIS REGISTRY: ANALYSIS OF DATA ON 71 CASES B. Myers, S. Marks, J. Thomson, C. Poynton, P. Shepherd, J. Cullis, D. Radia (NHS, Nottingham, United Kingdom) |
| 0657 | POLYCYTHEMIA VERA AS A PREDISPOSING FACTOR FOR AORTIC STENOSIS: INCIDENCE AND CORRELATION WITH BLOOD CELLS COUNT AND MUTATIONAL STATUS S. Siragusa, R. Barone, C. Caracciolo, R. Di Maggio, G. Fazio, L. D'Angelo, M. Montana, D. Caramazza, A. Malato, G. Saccullo, G. Pizzo, A. Casuccio, S. Novo, V. Abbadessa (University of Palermo, Palermo, Italy) |
| 0658 | DASATINIB FOR THE TREATMENT OF TREATMENT-REFRACTORY HYPEREOSINOPHILIC SYNDROME AND CHRONIC EOSINOPHILIC LEUKEMIA I.J. Dahabreh, S. Giannouli, C. Zoi, V. Gota, G. Leondaritis, C. Sambani, D. Loukopoulos, M. Voulgarelis, K. Zoi (Biomedical Research Foundation, Academy of Athens, Athens, Greece) |
| 0659 | HIGH RESOLUTION MELTING CURVE ANALYSIS: A SIMPLE, RELIABLE AND SENSITIVE METHOD OF DETECTION OF JAK2 EXON 12 MUTATIONS T. Lavabre-Bertrand, S. Carillo, L. Henry, E. Lippert, F. Girodon, I. Guiraud, C. Richard, C. Cleyrat, E. Jourdan, R. Kravlovics, S. Hermouet (Université Montpellier I - CHU Nîmes, Nimes, France) |
| 0660 | EXPRESSION OF A SET OF CELL-STROMA INTERACTING GENES IN PATIENTS WITH PRIMARY MYELOFIBROSIS A.L. Livun, T.M. Manshouri, R.K. Kusec, Y.Z. Zhang, H.M.K. Kantarjian, S.V. Verstovsek (MD Anderson, Houton, USA) |
| 0661 | THE IMPACT OF AZACITIDINE AND DECITABINE (HYPOMETHYLATING- AGENTS) IN MYELODYSPLASTIC SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS A. Kumar, F. List, I. Hozo, B. Djulbegovic (Moffitt Cancer Center, Tampa, USA) |
| 0662 | PRESENCE OF JAK2 V617F MUTATION IS A SINGLE STRONG PREDICTOR OF VASCULAR COMPLICATIONS IN PATIENTS WITH MPD M. Quitt, L. Gedzun, E. Shabad, A. Kotler, O. Valkovsky, M. Ballan, T. Shusterman, E. Mishchenko, N. Lindenfeld, A. Cassel (Carmel Medical Center, Haifa, Israel) |
| 0663 | JAK2 V617F MUTATION IN ACUTE MYELOID LEUKEMIA SECONDARY TO PH NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS C.R. Rinaldi, P. Rinaldi, V. Martinelli, R. Ciancia, A.M. Vannucchi, L. Gugliotta, T. Barbui, B. Rotoli, F. Pane (Federico II University, Naples, Italy) |
| 0664 | STUDY OF THE RELATION BETWEEN THE TIME COURSE OF THE JAK2V617F ALLELE BURDEN AND THE CLINICAL OUTCOME IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS); A SINGLE CENTER STUDY M.S. Sobas, M.M. Perez-Encinas, C. Quinteiro, T. Gonzalez, S. Suarez, D. Vilariño, N. Alonso, J. Diaz, A. Bendaña, S. Gonzalez, J.L. Bello-Lopez (Servicio de Hematologia, Hospital Clinico Universitario, Santiago de Comppostela, Spain) |
| 0665 | CRYPTIC 9P24 MICRODELETIONS COVERING HSA-MIR-101-2 ARE RECURRENT IN HEMATOLOGICAL MALIGNANCIES K. van Roosbroeck, I. Lahortiga, J. Finalet Ferreiro, J. van der Meulen, P. Vandenberghe, J. Cools, F. Speleman, P. Marynen, I. Wlodarska (Catholic University of Leuven, Leuven, Belgium) |
| 0666 | NOVEL T(X;14)(P11.4;Q32.33) RESULTING IN UPREGULATION OF GPR34 AND ACTIVATION OF THE NFKB PATHWAY IS RECURRENT IN MALT LYMPHOMAS M. Wlodarska, T. Tousseyn, L. De Leval, J. Finalet Ferreiro, H. Urbankova, L. Michaux, D. Dierickx, P. Wolter, P. Vandenberghe, P. Marynen, C. De Wolf- Peeters, M. Baens (Catholic University of Leuven, Leuven, Belgium |
| 0667 | DIFFERENTIAL EXPRESSION OF MICRORNAS IN PRIMARYCENTRAL NERVOUS (CNS) AND NODAL DIFFUSE LARGE B-CELL LYMPHOMAS L. Fischer, M. Hummel, A. Korfel, D. Lenze, E. Thiel (Charité Campus Benjamin Franklin, Berlin, Germany) |
| 0668 | CAL-, A SPECIFIC INHIBITOR OF THE P110DELTA ISOFORM OF PHOSPHATIDYLINOSITIDE 3-KINASE, FOR THE TREATMENT OF NON-HODGKINS LYMPHOMAS J. Lannutti, S.A. Meadows, A. Kashishian, B. Steiner, K.D. Puri, N.A. Giese(Calistoga Pharmaceuticals, Seattle USA) |
| 0669 | AMPLIFICATION AT 11Q23 TARGETS PROTEIN KINASE SIK2 IN DIFFUSE LARGE B-CELL LYMPHOMA S. Nagel, C. Meyer, H. Quentmeier, M. Zaborski, M. Kaufmann, H.G. Drexler, R.A.F. MacLeod (DSMZ, Braunschweig, Germany) |
| 0670 | IMPROVED DIFFERENTIAL DIAGNOSIS BETWEEN WHO-DEFINED MATURE B-CELL MALIGNANCIES USING INTEGRATED 8-COLOR FLOW CYTOMETRY AND NOVEL SOFTWARE FOR MULTIVARIATE ANALYSIS OF IMMUNOPHENOTYPIC DATA S. Böttcher, A. Rawstron, J. Flores, P. Lucio, R. de Tute, A. Mendonça, Q. Lecrevisse, T. Kalina, M. Kneba, J.J.M. van Dongen, A. Orfao, EuroFlow Onbehalf of the (University of Schleswig-Holstein, Campus Kiel, Kiel, Germany) |
| 0671 | ALTERATIONS OF CHEK2 GENE IN NON-HODGKIN LYMPHOMA PATIENTS O. Havranek, Z. Kleibl, P. Soucek, M. Trneny (Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic) |
| 0672 | DISTINGUISHING OF PRIMARY MEDIASTINAL B-CELL LYMPHOMAAND DIFFUSE LARGE B-CELL LYMPHOMA USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION H. Votavova, K. Forsterova, V. Campr, J. Stritesky, Z. Velenska, R. Pytlik, K. Kubackova, B. Prochazka, R. Kodet, M. Trneny (General Teaching Hospital, Prague, Czech Republic) |
| 0673 | BIOLOGIC EFFECTS OF P53 ACTIVATION BY NUTLIN-3A IN ALK+ALCL WITH UNMUTATED, MUTATED / PARTIALLY FUNCTIONAL AND MUTATED / NONFUNCTIONAL P53 GENE G. Rassidakis, E. Drakos, V. Atsaves, J. Li, I. Papanastasi, E. Schlette, L.J. Medeiros (National and Kapodistrian University of Athens, Athens, Greece) |
| 0674 | THE HISTONE DEACETYLASE INHIBITOR ITF235 (GIVINOSTAT) PROMOTES BURKITT'S LYMPHOMA CELL LINE DEATH MODULATINGMICRO-RNA AND TISSUE TRANSGLUTAMINASE 2 EXPRESSION R. Zappasodi, M. Di Nicola, C. Carlo-Stella, F. Baldan, M.V. Iorio, M. Magni, E. Tagliabue, C.M. Croce, A.M. Gianni (Istituto Nazionale Tumori, Milan, Italy) |
| 0675 | DIFFERENTIAL EXPRESSION OF SIN1 GENE PRODUCT IN NONHODGKIN AND HODGKIN LYMPHOMA CELL LINES AND TUMORS G. Rassidakis, P. Tsioli, P. Panayiotidis, T. Vassilakopoulos, E. Patsouris (National and Kapodistrian University of Athens, Athens, Greece) |
| 0676 | SELECTION OF MARKERS FOR IDENTIFICATION OF DISEASESPECIFIC PHENOTYPES FOR DIAGNOSIS AND MONITORING OFB-LYMPHOPROLIFERATIVE DISORDERS BY FLOW CYTOMETRY C. Rawstron, R.M. De Tute, J. Shingles, F.L. Bennett, S. Böttcher, P. Lucio, T. Kalina, E.A. MacIntyre, J.J.M. van Dongen, A. Orfao, A.S. Jack (Leeds Teaching Hospitals, Leeds, United Kingdom) |
| 0677 | MUTATION AND SINGLE NUCLEOTID POLYMORPHISM ANALYSIS IN HUMAN HERPESVIRUS 8-ASSOCIATED PRIMARY EFFUSION LYMPHOMA E. Boulanger, A. Marchio, S.S. Hong, P. Pineau (Oswaldo Cruz Institute (FIOCRUZ), Rio de Janeiro, Brazil) |
| 0678 | FOCUSED MICROARRAY FOR LYMPHOMA DIAGNOSTICS B. Tichy, K. Stano-Kozubik, J. Supikova, A. Janikova, I. Vasova, L. Smardova, J. Mayer, S. Pospisilova (University Hospital Brno and Faculty of medicine Masaryk University, Brno, Czech Republic) |
| 0679 | DETECTION OF HYPERMETHYLATION OF TUMOR SUPPRESSOR GENES IN OCULAR ADNEXAL LYMPHOMA USING MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) E. Coupland, H. Ma, A. Lo, D. Wong, H. Stein, E. Bertil (University of Liverpool, Liverpool, United Kingdom) |
| 0680 | DETECTION OF PLASMACYTOID (PLASMACYTIC) DIFFERENTIATION IN MARGINAL ZONE B CELL LYMPHOMAS (MZL) BY CD138 EXPRESSION C. Kalpadakis, G.A. Pangalis, P. Korkolopoulou, T.P. Vassilakopoulos, G. Levidou, M.C. Kyrtsonis, S. Sachanas, X. Yiakoumis, E.M. Dimitriadou, F.N. Kontopidou, M.P. Siakantaris, E. Patsouris, P. Panayiotidis, H. Papadaki, M.K. Angelopoulou (Department of Haematology, University of Crete, Athens, Greece) |
| 0682 | EXPRESSION OF CD66ABCE ON TUMOR CELLS IN NON-HODGKIN LYMPHOMAS AND MULTIPLE MYELOMA H. Mocikova, J. Karban, R. Pytlik, P. Klener, M. Trneny (First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic) |
| 0683 | SURVIVIN EXPRESSION IN AGGRESSIVE B-CELL LYMPHOMA M.K. Angelopoulou, P. Korkolopoulou, V. Salpeas, Z. Galani, T.P. Vassilakopoulos, G. Levidou, A. Anastasopoulou, K. Lilakos, S. Sachanas, M.P. Siakantaris, M.-C. Kyrtsonis, P. Panayiotidis, A. Androulaki, T. Papadaki, E. Patsouris, G.A. Pangalis (National and Kapodistrian University of Athens, Athens, Greece) |
| 0684 | BCL-, BCL-6 AND MYC REARRANGEMENTS AND CLINICAL OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA M.S. Sobas, M. Tojo, M. Tubio, M. Fraga, J.L. Bello, J. Forteza (Servicio de Hematologia, Hospital Clinico Universitario, Santiago de Compostela, Spain) |
TRANSFUSION MEDICINE
| 0685 | RHD GENE POLYMORPHISMS IN ALLOIMMUNIZED D-NEGATIVE INDIVIDUALS WITH HIGH RATE OF RACIAL ADMIXTURE |
|---|---|
| 0686 | ACTIVE HEMOVIGILANCE OF PEDIATRIC PATIENTS SUPPORTED WITH PLASMA COMPONENTS PREPARED WITH PHOTOCHEMICAL TREATMENT |
| 0687 | TRANSFUSION OF PLATELET COMPONENTS PREPARED WITH PHOTOCHEMICAL PATHOGEN INACTIVATION FOR SUPPORT OF SEVERE GLANZMANN THROMBASTHENIA DURING SURGICAL PROCEDURES |
| 0688 | LOSS OF THE RED CELL B ANTIGEN AND BLOOD GROUP CHANGE IS NOT ASSOCIATED WITH METHYLATION OF THE ABO GENE PROMOTER REGION IN A PATIENT WITH 5Q-MYELODYSPLASTIC SYNDROME |
| 0689 | A 10-YEAR LOOK-BACK ON USE OF CRYOPRECIPITATE IN A TERTIARY CARE HOSPITAL G. Zakout, M.A. Greiss (Aberdeen Royal Infirmary, Aberdeen, United Kingdom) |
| 0690 | THERAPEUTIC PLASMA EXCHANGE (TPE) FOR THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND HEMOLYTIC UREMIC SYNDROME (HUS) USING PLASMA PREPARED WITH PHOTOCHEMICAL PATHOGEN INACTIVATION: A ONE YEAR EXPERIENCE IN ROUTINE PRACTICE IN A REGIONAL BLOOD CENTER D. Kientz, M.L. Wiesel, I. Lanois, T. Krummel, B. Moulin, R. Herbrecht, J.P. Cazenave (EFS-Alace, Strasbourg, France) |
| 0691 | UNDERSTANDING TRANSFUSION OUTCOMES THROUGH CLINICAL REGISTRIES: VALIDATION OF A LINKAGE TECHNIQUE L. Phillips (Monash University, Melbourne, Australia) |
| 0692 | PLASMA EXCHANGE IN PATIENTS WITH TTP/HUS IN A BLOOD TRANSFUSION CENTRE: RETROSPECTIVE STUDY OF 46 CASES T.-M. Alemayehu, S. Theodoridou, T. Karafoulidou, P. Papadopoulou, S. Kiritsi, B. Duka, E. Ambatzoglou, G. Papaioannou (Hippokration Hospital, Thessaloniki, Greece) |
| 0693 | ALLOIMMUNIZATION TO ERYTHROCYTE ANTIGENS IN TRANSFUSION- DEPENDENT PATIENTS WITH HAEMOGLOBINOPATHIES: AN EXPERIENCE FROM A GREEK BLOOD TRANSFUSION SERVICE V. Kyriazi, L. Evliati, P. Koutsogianni, D. Kalantzis, E. Gerovaggeli, S. Saridakis, A. Megalou, M. Parara (Evaggelismos Hospital, Athens, Greece) |
| 0694 | PLATELET TRANSFUSION THRESHOLD FOR CENTRAL VENOUS CATHETER INSERTION IN ACUTE LEUKEMIAS K. Arn, K. Zeidler, O. Senn, U. Schanz, G. Stussi (University Hospital Zurich, Zürich, Switzerland) |
| 0695 | RED CELL ALLOIMMUNIZATION IN MULTITRANSFUSED CANCER PATIENTS A. Bilalis, E. Papadaki, E. Papoulia, L. Matou (Saint Savvas Oncology Hospital, Athens, Greece) |
| 0696 | CORD BLOOD BANKING: THE CONTRIBUTE OF BLOOD GROUP MOLECULAR GENOTYPING IN UNITS' VALIDATION P. Bergamaschi, I. Sbarsi, P. Isernia, A. Pasi, A. Marchesi, C. Badulli, B. Romano, V. Genovese, F. Garlaschelli, M. Guarene, C. Pizzochero, C. Monti, A. Livraghi, M. Martinetti, C. Perotti, L. Salvaneschi (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) |
| 0697 | HAEMOLYTIC DISEASE OF THE FETUS/NEWBORN SECONDARY TO ANTI-N/'N' W.C. Gordon, R.L. Soutar, K. Douglas, D. Frame, R. Green (Scottish National Blood Transfusion Service, Glasgow, United Kingdom) |
| 0698 | TREATMENT OF ORBISAC DERIVED BUFFY COAT PLATELETS WITH THE MIRASOL_ PATHOGEN REDUCTION TECHNOLOGY AND STORAGE IN ADDITIVE SOLUTION H. Reikvam, T. Hervig, S. Marschner, R. Goodrich (Institute of Internal Medicine, University of Bergen, Bergen, Norway) |
| 0699 | INTRAUTERINE TRANSFUSION RESULTS IN PRENATAL ANEMIA C Sanchez Ramos, A. Montoya, M. Jurado, S. Oyonarte, F. Molina (Hospital Universitario Virgen de las Nieves, Granada, Spain) |
| 0700 | PREDEPOSIT AUTOLOGOUS DONATION IN RADICAL PROSTATECTOMY: APHERESIS VS WHOLE BLOOD J.A. García-Erce, A. Borque, A. García-Jalón, B. Soria, M. Guillén, M.J. Gil, P. Gil, D. Rubio, M. Muñoz (Salud, Zaragoza, Spain) |
| 0701 | CONTRIBUTION OF HAEMATOTHERAPY TO THE TREATMENT OF MICROCIRCULATORY DISORDERS M. Blaha, E. Rencova, V. Blaha, R. Maly, M. Blazek, R. Prochazkova, C. Andrys, R. Zimova, H. Langrova (IInd Internal Clinic, Charles University, Hradec Kralove, Czech Republic) |
| 0702 | ROLE OF RITUXIMAB FOR TREATING PATIENTS WITH IDIOPATHIC TTP/HUS WITH OR WITHOUT ADAMTS-13 ANTIBODIES C. Caramazza, S. Siragusa, I. Abbene, L. Lo Coco, R. Di Trapani, G. Mazzola, S. Rizzo, R. Palazzolo, R. Barone, A. Malato, P. Ragonese, P. Aridon, V. Abbadessa, G. Quintini (Policlinico Universitario di Palermo, Palermo, Italy) |
| 0703 | THE EFFICACY AND EFFICIENCY PLATELET TRANSFUSION IN BUFFY COAT PLATELET COMPONENTS TREATED OR NOT BY INTERCEPT BLOOD SYSTEM M.I. Belkaid, N. Bakiri, M. Tsaramaro, G. Brochier, E. Chirpaz, F. Schooneman, T. Henni (CHR Nord Reunion, Saint Denis, Reunion) |
| 0704 | DATA REVIEW FROM THE PAVIA CORD BLOOD BANK: CORRELATION BETWEEN CORD BLOOD NUCLEATED AND HAEMATOPOIETIC STEM CELL COUNT AND BIRTHWEIGHT P. Bergamaschi, C. Capittini, M.P. Mercati, A. Marchesi, G. Viarengo, C. Del Fante, B. Romano, V. Genovese, A. Pasi, M. Guarene, C. Monti, C. Badulli, I. Sbarsi, F. Garlaschelli, C. Pizzochero, M. Cuccia, M. Martinetti, C. Perotti, L. Salvaneschi (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) |
| 0705 | HIGHER IRON SUCROSE DOSE IN A AMBULATORY ANAEMIA TREATMENT PROGRAM J.A. García-Erce, B. Soria, J. Cuenca, A. Borque, M. Guillén, P. Mayayo, A. García-Jalón, D. Rubio, M. Muñoz (Salud, Zarazoga, Spain) |
STEM CELL TRANSPLANTATION – DISEASE RELATED
| 0706 | TARGETED INTRAVENOUS BUSULFAN IN CHILDREN PRIOR STEM CELL TRANSPLANTATION FOR THALASSEMIA: PHARMACOKINETICS, TOXICITY AND TRANSPLANT OUTCOMES |
|---|---|
| 0707 | ADEQUATE MOBILIZATION OF CD34 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE INDUCTION THERAPY |
| 0708 | STEM CELL TRANSPLANTATION IN DIAMOND-BLACKFAN ANEMIA: A RETROSPECTIVE ANALYSIS |
| 0709 | HLA-E UP-REGULATION ON IFN-G-ACTIVATED AML BLASTS IMPAIRED CD94/NKG2A-DEPENDENT NK CYTOLYSIS FOLLOWING HAPLO-IDENTICAL HAEMATOPOIETIC STEM-CELL TRANSPLANTATION (SCT) |
| 0710 | PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM CELLS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH FLUDARABINE AND UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION J.R. Schriber, J. McCarty, J. McGuirk, G. Spitzer, J.P. Uberti, G. Calandra (Banner Good Samaritan Medical Center, Phoenix USA |
| 0711 | COMPARABLE OUTCOMES AFTER REDUCED-INTENSITY AND MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST OR SECOND REMISSION: A MATCHED-PAIR ANALYSIS S. Lee, J. Kwak, J. Kim, S. Park, B. Cho, K. Eom, Y. Kim, H. Kim, C. Min, S. Cho, D. Kim, J. Lee, W. Min, C. Kim (Catholic BMT Center, The Catholic University of Korea, Seoul, South-Korea) |
| 0712 | UNRELATED STEM CELL TRANSPLANTATION FOLLOWING TOTALBODY IRRADIATION-BASED MYELOABLATIVE CONDITIONING INADULTS WITH PHILADELPHIA-NEGATIVE HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA S. Lee, J. Kwak, J. Kim, S. Park, B. Cho, K. Eom, Y. Kim, H. Kim, C. Min, S. Cho, D. Kim, J. Lee, W. Min, C. Kim (Catholic BMT Center, The CatholicUniversity of Korea, Seoul, South-Korea) |
| 0713 | ALLOGENEIC VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSING FOLLICULAR LYMPHOMA: USE OF THE PROPENSITY SCORE TO REDUCE RECRUITMENT BIAS IN A RETROSPECTIVE COMPARATIVE STUDY F. De Fontbrune, D. Sibon, M. Resche-Rigon, S. Chevret, J. Brière, C. Gisselbrecht, C. Thiéblemont, G. Socié (Hopital Saint Louis, Paris, France) |
| 0714 | TREATMENT OF MANTLE CELL LYMPHOMA (MCL) BY ALLOGENEIC STEM CELL TRANSPLANTATION - A PRELIMINARY REPORT FROM THE TRIALS #060 AND #074 OF THE EAST GERMAN STUDY GROUP FOR HAEMATOLOGY AND ONCOLOGY (OSHO) W.H. Krüger, N. Basara, F. Schüler, D. Niederwieser, G. Behre, N. Grobe, H. Sayer, G. Maschmeyer, A. Haas, T. Kiefer, T. Neumann, G. Dölken (University-Hospital Greifswald, Greifswald, Germany) |
| 0715 | PRE-TRANSPLANT RISK ASSESSMENT FOR AML PATIENTS:COMBINED RISK FACTOR ANALYSIS MAY BE USED TO PREDICT OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED INTENSITY CONDITIONING P. Hemmati, T. Terwey, G. Massenkeil, P. Le Coutre, S. Neuburger, L. Lam, B. Dörken, R. Arnold (Charité Universitätsmedizin Berlin Campus Virchow Klinikum (CVK), Berlin, Germany) |
| 0716 | REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION DURING APLASIA IN PRIMARY HIGH-RISK AND RELAPSED ACUTE MYELOID LEUKEMIA F. Stölzel, J. Schetelig, U. Platzbecker, C. Thiede, T. Illmer, M. Schaich, M. Füssel, C. Theuser, M. Hänel, R. Mahlberg, G. Ehninger, M. Bornhäuser (Medizinische Klinik I, Dresden, Germany) |
| 0717 | IMPROVED SURVIVAL AFTER STEM CELL TRANSPLANTATION WITH KILLER-CELL-IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) / HLA MISMATCHED ALLOGRAFTS IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA. H. Martin, R. Richter, G. Bug, H. Serve, E. Seifried, C. Seidl (Goethe University, Frankfurt, Frankfurt, Germany) |
| 0718 | PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE I.N.N. Micallef, S.R. Tarantolo, P.A. McSweeney, L.M. Klein, G. Calandra, D. Huebner (Mayo Clinic, Rochester, USA) |
| 0719 | INTRAVENOUS BUSULFAN IN AUTOLOGOUS STEM CELL TRANSPLANTATION CONDITIONING REGIMEN FOR ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA. MULTICENTRE RETROSPECTIVE ANALYSIS C. Grande, P.J. García Sánchez, J. de la Rubia, D. Serrano, M. López Duarte, R. García Boyero, P. Rosique, I. Heras, R. Martínez, J.J. Lahuerta (Hospital 12 de Octubre, Madrid, Spain) |
| 0720 | HIGHER INFUSED CD34+ HEMATOPOIETIC STEM CELL DOSE CORRELATES WITH EARLIER LYMPHOCYTE RECOVERY ANDBETTER CLINICAL OUTCOME AFTER AUTOLOGOUS STEM CELLTRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA C. Suh, D.H. Yoon, B.S. Sohn, J.E. Kim, C.H. Yoo, S. Kim, D.H. Lee, C.J. Park, J.R. Huh (Asan Medical Center, University of Ulsan College of Medicine, Seoul, South-Korea) |
| 0721 | SEARCH OF AN UNRELATED DONOR FOR PATIENTS WITH HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, UNICENTRIC STUDY A.P. Iori, V. Valle, A. Piciocchi, G.F. Torelli, L. Malandruccolo, G. Meloni, A.M. Testi, W. Barberi, A. Vitale, F. Milano, B. Lucarelli, E. Iannella, F. Natalino, M. Perrone, L. Laurenti, R. Ricci, C. Minotti, W. Arcese, R. Foà (Hematology, Rome, Italy) |
| 0722 | SINGLE CENTER COMPARATIVE STUDY OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION VERSUS HLA MATCHED FAMILY DONOR TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA AND HIGH RISK MYELODISPLASTIC SYNDROME A. de Laiglesia, I. Vicuña, A. Sebrango, G. Bautista, C. Regidor, R. Forés, E. Ojeda, J.A. García-Marco, S. Gil, I. Krsnik, B. Navarro, I. Sanjuan, J.R. Cabrera, M.N. Fernández (Hospital Universitario Puerta de Hierro, Madrid, Spain) |
| 0723 | SECOND ALLOGENEIC STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT IN RELAPSED HAEMATOLOGICAL MALIGNANCIES: FEASIBILITY AND OUTCOME IN 26 PATIENTS M.T. Lupo Stanghellini, A.A. Assanelli, R. Crocchiolo, D. Clerici, M. Tassara, V. Calbi, M. Bernardi, M. Marcatti, C. Corti, M.G. Carrabba, F. Lunghi, E. Guggiari, L. Camba, C. Bonini, J. Peccatori, F. Ciceri (San Raffaele Scientific Institute, Milan, Italy) |
| 0724 | OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 30 ACUTE MYELOID LEUKEMIA PATIENTS AGED 60 YEARS OR OLDER A. Candoni, E. Simeone, A. Sperotto, M. Tiribelli, A. Geromin, M. Cerno, F. Patriarca, M. Battista, R. Fanin (Division of Hematology, Udine, Italy) |
| 0725 | TANDEM AUTO-SCT AND REDUCED-INTENSITY CONDITIONING (RIC) ALLO-SCT FOR RELAPSED OR TRANSFORMED AGGRESSIVE B CELL NON-HODGKIN'S LYMPHOMA (NHL) M.D. Clavert (Hotel Dieu CHU, Nantes, France) |
| 0726 | COMPLETE HEMATOLOGIC REMISSION BUT NOT MOLECULAR REMISSION IS ASSOCIATED WITH PROLONGED SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION F. Folber, M. Doubek, I. Palasek, D. Dvorakova, J. Mayer (University Hospital Brno, Brno, Czech Republic) |
STEM CELL TRANSPLANTATION – MISCELLANEOUS
| 0727 | SMALL HUMAN ß-DEFENSIN-3 DERIVED PEPTIDE INDUCES RAPID AND PREFERENTIAL MOBILIZATION OF MOUSE HEMATOPOIETIC PROGENITOR CELLS VIA SDF-1 SECRETION |
|---|---|
| 0728 | HEMATOPOIETIC CELLS RECEIVE A STRONG IMPRINTING WHEN PASSING THROUGH BONE MARROW: RESULTS OF A COMPARISON BETWEEN INTRABONE VERSUS INTRAVENOUS TRANSPLANTATION |
| 0729 | HUMAN MESENCHYMAL STEM CELLS CAN AMELIORATE HEMATOPOIETIC FUNCTION AFTER CHEMO-RADIOTHERAPY INDUCED STROMAL DAMAGE |
| 0730 | CXCL12 RS1801157 POLIMORPHISM IS ASSOCIATED WITH DECREASED MRNA CXCL12 EXPRESSION AND HIGHER HEMOPOIETIC PROGENITOR CELL (HPC) MOBILIZATION |
| 0731 | REPORT OF 15-YEAR EXPERIENCE OF THE MILANO CORD BLOOD BANK: CLINICAL OUTCOMES OF SINGLE UNRELATED CORD BLOOD TRANSPLANTS A. Ruggeri, L. Lecchi, I. Ionescu, D. Purtill, K. Boudjedir, E. Gluckman, V. Rocha, P. Rebulla (Eurocord-Saint Louis, Paris, France) |
| 0732 | IRON OVERLOAD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) EVALUATED BY SUPERCONDUCTING QUANTUM INTERFERENCE DEVICE (SQUID) A. Busca, M. Falda, P. Manzini, S. D'Antico, F. Longo, F. Locatelli, A. Chiappella, S. D'Ardia, R. Calabrese, A. Piga (Hematology , AOU San Giovanni Battista, Turin, Italy) |
| 0733 | FREEZE-DRYING OF HUMAN UMBILICAL CORD BLOOD MONONUCLEAR CELLS Y. Natan, A. Nagler, M. Binyamini, R. Mayerov, A. Arav (Core Dynamics, Ness Ziona, Israel) |
| 0734 | IMPACT OF VITAMIN D RECEPTOR GENE POLYMORPHISMS ON CLINICAL OUTCOMES OF SIBLING HLA-MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION H.J. Cho, J.H. Kim, N. Kim, E.K. Ra, S.S. Yoon, Y.C Hong, H.K. Kim, S.S. Park, D.S. Lee, S. Park, M.H. Park, B.K. Kim, I. Kim (Seoul National University Hospital, Seoul, South-Korea) |
| 0735 | IMMUNOBIOLOGICAL EFFECTS OF NKT CELLS FROM ACUTE MYELOID LEUKEMIA PATIENTS IN A PRE-CLINICAL ANTILEUKEMIC TRIAL H.J. Kim, J.B. Choi, J.H. Moon, T.H. Lee, H.S. Kang, W.S. Min (Catholic HSCT Center, Seoul, South-Korea) |
| 0736 | THE EFFECT OF HUMAN UMBILICAL CORD BLOOD CD34+ PROGENITOR CELLS TRANSPLANTATION ON DIABETIC MICE M. Attia, A. Husein, M. Awad, A. Abdelal, M. Elbarbary (Faculty of Medicine - Ismailia University, Ismailia, Egypt) |
| 0737 | A COCKTAIL TO BYPASS FETAL BOVINE SERUM LIMITATIONS FOR THE PRODUCTION OF UMBILICAL CORD DERIVED MESENCHYMAL STROMAL STEM CELLS FOR CLINICAL USE K. Chieregato, S. Castegnaro, D. Madeo, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy) |
| 0738 | POLYMORPHISMS OF MTHFR AND CLINICAL OUTCOMES IN ALLOGENEIC STEM CELL TRANSPLANTATION S. Giammarco, P. Chiusolo, S. Bellesi, S. Marietti, D.G. De Ritis, E. Metafuni, S. De Matteis, G. Leone, S. Sica (Università Cattolica S. Cuore, Rome, Italy) |
| 0739 | PROGNOSTIC FACTORS FOR SUCCESSFUL MOBILIZATION AND COLLECTION OF PERIPHERAL BLOOD STEM CELLS (PBSC) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. A STUDY OF 209 PATIENTS M.K. Angelopoulou, T.P. Vassilakopoulos, S. Masouridis, M. Moschogiannis, P. Tsirkinidis, V. Pappi, Z. Galani, V. Kalotychou, K. Konstantoudakis, E. Dimitriadou, C. Kalpadaki, M. Dimopoulou, S. Kokoris, N.-A. Vyniou, E. Variamis, M.P. Siakantaris, Y. Rombos, M.-C. Kyrtsonis, P. Panayiotidis, G.A. Pangalis (National and Kapodistrian University of Athens, Athens, Greece) |
| 0740 | AXP IN ROUTINE CORD BLOOD BANKING: CRITICAL ANALYSIS OF DIFFERENT VOLUME REDUCTION METHODOLOGIES P. Solves, V. Mirabet, A. Blanquer, F. Delgado, L. Larrea, A. Torres, A. Andres, I. Aznar, M. Guillen, R.J. Roig (Transfusion Center, Valencia, Spain |
| 0741 | PLATELET ENGRAFTMENT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES FOLLOWING UNMANIPULATED HAPLOIDENTICALBLOOD AND MARROW TRANSPLANTATION: EFFECTS OF CD34+CELL DOSE AND DISEASE STATUS H. Xiao-Jun, Y.J. Chang, L.P. Xu, D.H. Liu, K.Y. Liu, W. Han, Y.H. Chen, Y. Wang, H. Chen, J.Z. Wang, X.H. Zhang, X.Y. Zhao (Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China) |
NOVEL THERAPEUTICS, TARGETED THERAPIES AND GENE
THERAPY - PRECLINICAL
| 0742 | A VON WILLEBRAND FACTOR INHIBITORY ANTIBODY EFFECTIVELY INHIBITS ARTERIAL THROMBOSIS IN A HIGH SHEAR RATE MODEL IN BABOONS |
|---|---|
| 0743 | LEUKEMIA INDUCED BY ALTERED TRK-SIGNALING IS SENSITIVE TO TREATMENT WITH MTOR INHIBITORS IN A PRECLINICAL MODEL |
| 0744 | PRELIMINARY EVIDENCE OF CLINICAL ACTIVITY IN A PHASE 1 STUDY OF CAL-, A POTENT SELECTIVE INHIBITOR OF THE P110DELTA ISOFORM OF PHOSPHATIDYLINOSITOL 3-KINASE, IN PATIENTS WITH B-CELL MALIGNANCIES |
| 0745 | EPIGENETIC THERAPY WITH 5-AZACITIDINE, VALPROIC ACID, AND ATRA IN PATIENTS WITH HIGH-RISK AML OR MDS: RESULTS OF THE FRENCH VIVEDEP PHASE II STUDY |
| 0746 | PRECLINICAL EXPERIENCES WITH THE NOVEL CALICHEAMICINCONJUGATED CD22 ANTIBODY INOTUZUMAB OZOGAMICIN (CMC- 544) IN THE TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA F. de Vries, C.M. Zwaan, M. de Bie, J.S.A. Voerman, J.J.M. van Dongen, H.H. Patel, V.H.J. van der Velden (Erasmus MC, Rotterdam, The Netherlands) |
| 0747 | INTERFERON-ALPHA-ENGINEERED MULTIPOTENT MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF MYELOMA M. Tinelli, M. Mazzocco, M. Martini, F. Mosna, V. Lisi, S. Indraccolo, L. Moserle, T. Cestari, A.P. Riviera, F. Bifari, G. Tridente, G. Pizzolo, S. Sartoris, M. Krampera (Department of Clinical and Experimental Medicine, Verona, Italy) |
| 0748 | HEAT SHOCK PROTEIN 32-TARGETING DRUGS INDUCE GROWTH ARREST AND APOPTOSIS IN LEUKEMIC CELLS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) R.A.M. Meyer, H. Herrmann, K.V. Gleixner, S. Cerny-Reiterer, A. Gruze, R. Hubmann, M. Shehata, M. Mayerhofer, W.R. Sperr, W.F. Pickl, J.V. Melo, H. Nakamura, U. Jäger, H. Maeda, P. Valent (Medical University of Vienna, Vienna, Austria) |
| 0749 | PROTEOMIC ANALYSIS OF PKC-BETA INHIBITOR ENZASTAURIN-TREATED MANTLE CELL LYMPHOMA M. Weinkauf, M. Rieken, A. Pastore, G. Hutter, Y. Zimmermann, W. Hiddemann, M. Dreyling (CCG Leukemia, Campus Grosshadern Medical Clinic III and Helmholtz Center, Munich, Germany) |
| 0750 | THE BH3 MIMETIC GX015-070 (OBATOCLAX) INDUCES APOPTOSIS AND GROWTH INHIBITION IN NEOPLASTIC MAST CELLS B. Peter, K Aichberger, K.V. Gleixner, E. Hadzijusufovic, K. Schuch, W.F. Pickl, M. Willmann, P. Valent (Medical University of Vienna, Vienna, Austria) |
| 0751 | QUANTITATIVE MEASUREMENT OF NUCLEAR TRANSLOCATION OF NF-KB AND STAT-3 AS PARAMETER OF RESPONSE TO TARGETED TREATMENTS IN IMMUNOPHENOTYPICALLY DEFINED CELLS IN ACUTE MYELOID LEUKEMIA H. Minderman, K. O'Loughlin, C. Collins, V . Venkatachalam, T. George, P.K. Wallace (Roswell Park Cancer Institute, Buffalo, USA) |
| 0752 | ACTIVITY OF MLN492, A NOVEL FIRST IN CLASS SMALL MOLECULE INHIBITOR OF THE NEDD8 ACTIVATING ENZYME (NAE), IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML) T. Swords, K. Kelly, P. Smith, D. Mahalingam, M. O'Dwyer, S. Nawrocki, F. Giles, J. Carew (Cancer Therapy and Reseach Center, San antonio, USA) |
| 0753 | OVERCOMING DRUG RESISTANCE WITH SGI-1776: A NOVEL PIM KINASE INHIBITOR WITH POTENT PRECLINICAL ACTIVITY IN ACUTE MYELOID LEUKEMIA (AML) T. Swords, K. Kelly, D. Mahalingam, M. O'Dwyer, S. Nawrocki, F. Giles, J. Carew (Cancer Therapy and Reseach Center, San Antonio, USA) |
| 0754 | INTERFERENCE WITH AML1/ETO LEUKEMOGENIC FUNCTION BY CELL-PENETRATING PEPTIDES TARGETING THE OLIGOMERIZATIONDOMAIN Y. Becker, C. Wichmann, M. Grez (Georg-Speyer-Haus, Frankfurt, Germany) |
| 0755 | TUMOR MEMBRANE-BOUND DIMERIC IL-2 AND A BISPECIFIC CD3X19 ANTIBODY INDUCE CYTOTOXIC T-CELL STIMULATORY CAPACITY OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA CELLS M. Notter (Charité, Berlin, Germany) |
| 0756 | BI-213 LABELED ANTI-CD20 MONOCLONAL ANTIBODIES INDUCE APOPTOSIS AND OVERCOME CHEMORESISTANCE IN NONHODGKIN’S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA CELLS C. Friesen, M. Roscher, I. Hormann, A. Morgenstern, F. Bruchertseifer, C. Apostolidis, Th. Zenz, S. Stilgenbauer, E. Miltner (Institute for Legal Medicine, University Ulm, Ulm, Germany) |
| 0757 | LEUKEMIA CELL-SELECTIVE UPTAKE OF CYTARABINE AND DAUNORUBICIN IN THE BONE MARROW COMPARTMENT MEDIATED BY CPX-351 LIPOSOME INJECTION D. Mayer, S. Lim, G. Tardi, X. Xie, M Fan, X Huang, O Harasym (Celator Pharmaceuticals, Vancouver, Canada) |
| 0758 | INDUCTION OF APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUCEMIA (CLL) CELLS BY THE PARA-ISOMER OF NITRIC OXIDE-DONATING ACETYLSALICYLIC ACID (P-NO-ASA) AT LOW MICROMOLAR CONCENTRATIONS R. Razavi, I. Gehrke, R.K. Gandhirajan, J. Paesler, A. Filipovich, F. Erdfelder, M. Hertweck, S. Uhrmacher, M. Hallek, K.-A. Kreuzer (Uniklinik Koeln, Koeln, Germany) |
| 0759 | ZALYPSIS, A NOVEL AND SELECTIVE ANTILEUKEMIC AGENT TARGETING INMATURE BLAST CELL POPULATIONS E. Colado, P. Maiso, L. González, E.M. Ocio, M.B. Vidriales, A. Pandiella, J.F. San Miguel (Hospital Universitario de Salamanca- Centro deInvestigación del Cáncer-IBMCC (U, Salamanca, Spain) |
| 0760 | K-RAS SHRNA POTENTIATES FARNESYLTRANSFERASE INHIBITOR (FTI) EFFICACY IN CHRONIC MYELOID LEUKEMIA A. Morgan, F. Onono, M. Scherr, L. Venturini, I. Dallman, A. Ganser, C.W.M. Reuter (Hannover Medical School, Hannover, Germany) |
| 0761 | EXPLOITING THE UNIQUE MECHANISM OF ACTION OF SAPACITABINE (CYC682) TO OBTAIN SYNERGY WITH OTHER THERAPEUTIC AGENTS FOR CLINICAL USE IN ACUTE MYELOID LEUKEMIA S.M. Frame, R.H. MacKay, M. Hogben, C. Connolly, S. Anderson, I.N. Fleming, S. Davis, D. Blake, S.R. Green (Cyclacel Ltd, Dundee, United Kingdom) |
RED BLOOD CELLS AND IRON III
| 0762 | THE EFFECT OF DEFERASIROX ON MYOCARDIAL IRON OVERLOAD AND CARDIAC FUNCTION: A PROSPECTIVE INDEPENDENTMONOCENTRIC STUDY USING CARDIOVASCULAR MAGNETIC RESONANCE T2* (MRI T2*) |
|---|---|
| 0763 | DEFERASIROX REDUCES CARDIAC IRON BURDEN IN CHRONICALLY TRANSFUSED B-THALASSEMIA PATIENTS WITH MILD-TO-MODERATE CARDIAC SIDEROSIS AS DEMONSTRATED BY MRI T2* |
| 0764 | FLUCTUATION OF CYSTATIN C CONCENTRATION DURING DEFERASIROX TREATMENT IN THALASSEMIC PATIENTS MAYREFLECT HEMODYNAMIC CHANGES |
| 0765 | MALE AND FEMALE FERTILITY AND PREGNANCY IN THALASSAEMIA MAJOR, THE WHITTINGTON EXPERIENCE |
| 0766 | INFLAMMATORY MEDIATORS INDUCE AUGMENTED ADHESIVE PROPERTIES IN NEUTROPHILS FROM CONTROL AND SICKLECELL DISEASE INDIVIDUALS, IN ASSOCIATION WITH ALTEREDINTRACELLULAR CYCLIC AMP I. Miguel, A. Canalli, B. Almeida, T.O. Saad, F. Costa, N. Conran (Unicamp, Campinas, Brazil) |
| 0767 | NEUTROPHILS ARE SUBJECT TO BOTH ANTI AND PRO APOPTOTIC STIMULI IN THE SERUM OF SICKLE CELL DISEASE INDIVIDUALS C. Almeida, F. Pereira, I. Lorand-Metze, C. Franco-Penteado, S. Saad, F. Costa, N. Conran (Unicamp, Campinas, Brazil) |
| 0768 | CREATING A EUROPEAN NETWORK OF EXPERT CENTRES ON RARE ANAEMIAS: A NEW CHALLENGE FOR ENERCA 3 J.L. Vives Corrons, M.d.M. Mañú Pereira (Hospital Clínic, Barcelona, Spain) |
| 0769 | BILIRUBIN LEVELS AND TATA BOX POLYMORPHISM OF UGT1A1 GENE ASSOCIATED TO GILBERT'S SYNDROME IN THE DIFFERENT CLINICAL FORMS OF HEREDITARY SPHEROCYTOSIS S. Rocha (Faculdade de Farmácia/Instituto de Biologia Molecular e Celular (IBMC), Porto, Portugal) |
| 0770 | CARDIAC IRON OVERLOAD AFTER TREATMENT WITHANTHRACYCLINES IS MODULATED BY HFE GENOTYPE A. Cascales, B. Sanchez-Vega, F. Pastor, J. Corral, V. Vicente, F. Ayala (Centro Hemodonacion, Murcia, Spain) |
| 0771 | MRI LIVER IRON MEASUREMENT IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD: DIFFERENT TECHNIQUES, DIFFERENT RESULTS, DIFFERENT THERAPEUTIC CONSEQUENCES? H. Cario, A. Schulz, M. Juchems, A. Wunderlich (University Hospital, Ulm, Germany) |
| 0772 | EFFICACY AND SAFETY OF DEFERASIROX IN CHELATION-NAÏVE PATIENTS WITH B-THALASSAEMIA MAJOR: RESULTS FROM THE LARGE-SCALE EPIC STUDY A. Taher, A. Koren, H. Tamary, M.D. Cappellini, J.B. Porter, D. Habr, G. Domokos, B. Roubert, V. Viprakasit (American University of Beirut Medical Center, Beirut, Lebanon) |
| 0773 | GENE EXPRESSION OF THE IL-6/STAT-3/HAMP SIGNALING PATHWAY IN MONONUCLEAR CELLS IN SICKLE CELL DISEASE S. Gambero, M.A.C. Bezerra, C. Lanaro, C.F. Franco-Penteado, K.Y. Fertrin, M.R.B. Mello, D.M. Albuquerque, S.T.O. Saad, A.S. Araujo, F.F. Costa (UnicampP, Campinas, Brazil) |
| 0774 | OXIDATIVE STRESS AND GENE EXPRESSION OF INFLAMMATORY MEDIATORS IN MONONUCLEAR CELLS IN SICKLE CELL DISEASE K. Fertrin, M. Bezerra, C. Lanaro, C. Franco-Penteado, S. Gambero, M. Mello, D. Albuquerque, S. Saad, A. Araujo, F. Costa (Unicamp, Campinas, Brazil) |
| 0775 | ACUTE HUMAN PARVOVIRUS B19 INFECTION AND NEPHROTIC SYNDROME IN PATIENTS WITH SICKLE CELL DISEASE S Quek, C. Sharpe, N. Dutt, D. Rees, S. Height, M. Zuckerman, S.L. Thein (King's College Hospital NHS Trust London, London, United Kingdom) |
| 0777 | C-TERMINAL DELETION IN THE ALAS2 GENE AND X-LINKED DOMINANT PROTOPORPHYRIA E. Di Pierro, V. Brancaleoni, D. Tavazzi, M.D. Cappellini (Foundation Policlinico-University of Milan, Milan, Italy |
PLATELETS AND THROMBOCYTOPENIA II
| 0778 | ACCURACY OF PLATELET COUNTING BY HAEMATOLOGY ANALYSERS AND ITS POTENTIAL IMPACT ON THE TRANSFUSION DECISION-MAKING PROCESS |
|---|---|
| 0779 | CLINICAL OUTCOME AND RISK FACTOR ANALYSES IN THROMBOTIC THROMBOCYTOPENIC PURPURA-HEMOLYTIC UREMIC SYNDROME PATIENTS WHO UNDERWENT THERAPEUTIC PLASMA EXCHANGE |
| 0780 | AUDIT ASSESSING POSSIBLE RISK FACTORS FOR THROMBOTIC MICROANGIOPATHIES IN A SINGLE CLINICAL APHERESIS UNIT |
| 0781 | ANALYSIS OF CARBONYLATED PROTEINS IN HUMAN BLOOD PLATELETS |
| 0782 | PLATELET MICROPARTICLES IN PEDIATRIC IMMUNE THROMBOCYTOPENIC PURPURA A. Tantawy, R. M.Matter, A. A.S.Hamed, M. A.S.Eltelbany (Faculty of Medicine, Ain Shams University, Cairo, Egypt) |
| 0783 | INCREASED LEVELS OF PLATELET-LEUCOCYTE COMPLEXES IN BEHCET'S DISEASE PATIENTS WITH MAJOR VASCULAR INVOLVEMENT G.E. Pamuk, Ö.N. Pamuk, H. Örüm, M. Demir, B. Turgut (Trakya University Medical Faculty, Division of Hematology, Edirne, Turkey) |
| 0784 | HELICOBACTER PYLORI ERADICATION IMPROVES PLATELET COUNT IN INFECTED CHILDREN WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA M. Ferrara (Second University of Naples, Naples, Italy |
| 0785 | DOES ANTI-TNF THERAPY CAUSE ANY CHANGE IN PLATELET ACTIVATION IN ANKYLOSING SPONDYLITIS PATIENTS? G.E. Pamuk, Ö.N. Pamuk, H. Örüm, B. Turgut, M. Demir (Trakya University Medical Faculty, Division of Hematology, Edirne, Turkey) |
| 0786 | IDIOPATHIC THROMBOCYTOPENIC PURPURA AND AUTOIMMUNE HEMOLYTIC ANEMIA IN THE PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY K. Moazzami, N. Rezaei, A. Aghamohammadi (University of Tehran, Medical School, Tehran, Iran) |
| 0787 | ABNORMAL HEPATOBILIARY LABORATORY VALUES AMONG PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) D. Bennett, C. Enger, K.L. Dawson, A. Brainsky, M. Aivado, D. Theodore (GlaxoSmithKline, Philadelphia, USA) |
| 0788 | CHRONIC AND RECURRENT IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD - SINGLE INSTITUTION EXPERIENCE K. Martinova, O. Muratovska, S. Glamocanin, Z. Antevska-Trajkova, B. Coneska-Jovanova, S. Koceva (University Children's Hospital, Skopje, Macedonia) |
| 0789 | ITP AND CELIAC DISEASE: A NON SPORADIC ASSOCIATION F. Cecere, G. Pollio, A. Mangione, A.G. De Anseris, R. Albano, G. Menna (Aorn”s.Giovanni di Dio e Ruggi d'Aragona”, Salerno, Italy) |
| 0790 | CLINICAL AND RADIOLOGIC EVALUATION OF CYTOMEGALOVIRUSINDUCED THROMBOCYTOPENIA IN INFANTS BETWEEN 1 MONTH AND 6 MONTHS OF AGE S.Y. Kim, E.S. Park, H.J. Kim (Chungnam National University, Daejeon, South-Korea) |
| 0791 | NATIONAL SURVEY ON PREVALENCE AND TREATMENT OF IMMUNE THOMBOCYTOPENIC PURPURA IN POLAND - PLATE QUESTIONNAIRE M. Zawilska, M. Podolak-Dawidziak, K. Chojnowski, J. Windyga, J. Zdziarska (J.Strus Hospital, Poznan, Poland) |
| 0792 | DYNAMICS OF PLATELET MORPHOFUNCTIONAL STATUS IN ANTICOAGULANT THERAPY E.A. Vlasova, I. Vasilenko, V. Suslov, V. Samoylenko (Russian gerontological scientific clinical center, Moscow, Russian Federation) |
MYELODYSPLASTIC SYNDROMES II
| 0793 | PROMOTER HYPERMETHYLATION STATUS OF THE MEG3 AND SNRPN IMPRINTED GENES IN MYELODYSPLASTIC SYNDROMES |
|---|---|
| 0794 | SERUM ERYTHROPOIETIN AT DIAGNOSIS IN LOW GRADE MYELODYSPLASTIC SYNDROME CORRELATES WITH BOTH RED CELL ZINC PROTOPORPHYRIN AND SERUM LDH AND MAY REFLECTSEVERITY OF INEFFECTIVE ERYTHROPOIESIS |
| 0795 | ANALYSIS OF EXPRESSION OF THE WNT-ANTAGONIST SFRP1 AND QUANTIFICATION OF ITS PROMOTER METHYLATION BY PYROSEQUENCING IN BONE MARROW MONONUCLEAR CELLS FROM PATIENTS WITH DIFFERENT RISK-TYPES OF MDS, ALL, AND AML |
| 0796 | A NOVEL PEDIGREE WITH HETEROZYGOUS GERMLINE RUNX1 MUTATION CAUSING FAMILIAL MDS-RELATED AML - CAN THESE FAMILIES SERVE AS A MULTISTEP MODEL FOR LEUKAEMIC TRANSFORMATION IN MDS AND AML? |
| 0797 | DECREASE IN INTRA- AND EXTRA-CELLULAR FREE IRON SPECIESAND OXIDATIVE STRESS PARAMETERS AND INCREASE IN SERUM AND URINARY HEPCIDIN DURING TREATMENT WITH DEFERASIROX IN IRON-LOADED PATIENTS WITH MDS H. Ghoti, E. Fibach, D. Merkel, J. Amer, A. Nagler, I. Levi, S. Grisariu, E. Naparstek, A. Ackerstein, G. Olbina, M. Westerman, T. Ganz, E.A. Rachmilewitz (Edith Wolfson Medical Center, Holon, Israel) |
| 0798 | COMPARISON OF ALTERNATIVE SPLICING OF THE RETROVIRAL RECEPTOR/HEME EXPORTER FLVCR1 IN MYELODYSPLASTIC SYNDROMES AND NORMAL ERYTHROPOIESIS WITH DIAMOND BLACKFAN ANEMIA D.P. Steensma, J.C. Porcher (Mayo Clinic, Rochester, USA) |
| 0799 | CD34 CELLS ARE UNDER OXIDATIVE STRESS - POSSIBLE IMPLICATION IN MDS PATHOGENESIS A. C. Gonçalves, E. Cortesão, V. Alves, A. I. Espadana, L. Rito, E. Magalhães, S. Pereira, C. Moucho, A. Pereira, I. Sousa, A. Teixeira, A.B. Sarmento- Ribeiro (Faculty of Medicine, University of Coimbra, Coimbra, Portugal) |
| 0800 | JAK2 V617F MUTATION IN PRIMARY MYELODYSPLASTIC SYNDROMES: A MULTICENTER RETROSPECTIVE STUDY I.J. Dahabreh, K. Manola, A. Galanopoulos, C. Zoi, S. Giannouli, C. Stavropoulou, I. Vlachadami, K. Kalderi, M. Fisfis, K. Stefanoudaki,E. Terpos, V. Gota, Z. Kartasis, E. Palliou, A. Katsigiannis, P. Roussou, N. Anagnostopoulos, S. Lafioniatis, A. Palliou, D. Loukopoulos, C. Sambani, M. Voulgarelis, K. Zoi (Biomedical Research Foundation, Academy of Athens, Athens, Greece) |
| 0801 | SUPPRESSION OF THE DNA DAMAGE RESPONSE IN ACUTE MYELOID LEUKEMIA VERSUS MYELODYSPLASTIC SYNDROME S. Boehrer, L. Adès, C. Gardin, W.K. Hofmann, P. Fenaux, G. Kroemer (Hôpital Avicenne, Bobigny, France) |
| 0802 | IMMUNE EFFECTORS AND REGULATORY T CELLS IN MYELODYSPLASTIC SYNDROMES (MDS) F. Alfinito, M. Sica, L. Luciano, R. Della Pepa, C. Palladino, I. Ferrara, U. Giani, G. Ruggiero, G. Terrazzano (University of Naples Federico II, Naples, Italy) |
| 0803 | NANOG MRNA IS HIGHLY EXPRESSED IN MDS CELLS AND DURING ERYTHROID DIFFERENTIATION J. Xavier (Hemocentro Unicamp, Campinas, Brazil) |
| 0804 | EXPRESSION PATTERNS OF CELL CYCLE AND DNA REPLICATION GENES DISCRIMINATE EARLY AND ADVANCED MDS A. Vasikova, M. Belickova, E. Budinska, J. Cermak (Institute of Hematology and Blood Transfusion, Prague, Czech Republic) |
| 0805 | LEUKEMIC TRANSFORMATION OF MDS PATIENTS DYSPLAYING ABNORMAL CYTOGENTICS WITHOUT DEFINITE DYSPLASIA IN BONE MARROW CELLS S.Y. Kim, M.S Kim, K.J Han, M. Lee, W.S. Min, J.W. Lee (KonKuk University Medical Center, Seoul, South-Korea) |
| 0806 | THE USE OF IRON CHELATION THERAPY FOR TRANSFUSION DEPENDENT MYELODYSPLASTIC SYNDROME PATIENTS: A CROSS-SECTIONAL STUDY IN BELGIUM M Delforge, D. Selleslag, A. Triffet, P. Mineur, Y. Beguin, L. Noens, W. Pluymers, C. Ravoet (University Hospital Gasthuisberg, Leuven, Belgium) |
| 0807 | LENALIDOMIDE TREATMENT MODULATES CELL SURFACE MOLECULE EXPRESSION AND CYTOKINE SECRETION OF HUMAN MESENCHYMAL STROMAL CELLS FROM HEALTHY DONORS AND MDS PATIENTS M. Wobus, G. Duennebier, M. Bornhaeuser, G. Ehninger, U. Platzbecker (University Hospital Dresden, Dresden, Germany) |
| 0808 | INCREASE IN BONE MARROW IMMATURE NON-LYMPHOID EARLY PRECURSORS PREDICTS A SHORT SURVIVAL IN MYELODYSPLASTIC SYNDROMES I. Lorand-Metze, S.C. Reis, F. Traina, E. Ribeiro, S.T.O. Saad, K.M. Metze (State University of Campinas, Campinas, Brazil) |
| 0809 | LINK BETWEEN OCCUPATIONAL EXPOSURE TO HEAVY METALS AND HIGH RISK MYELODYSPLASTIC SYNDROMES A. Divies, F. Hérin, K. Delavigne, E. Bart-Delabesse, N. Dastugue, G. Laurent, D. Adoue, O. Beyne-Rauzy (CHU Purpan, Toulouse, France) |
| 0810 | DIFFERENCES IN EXPRESSION OF GENES INVOLVED IN NUCLEAR FACTOR KAPPA B(NFKB) PATHWAY AFTER ANALYSIS BY QUANTITATIVE POLYMERASE CHAIN REACTION ARRAYS IN MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS E. Rouka, D. Adamidou, M. Alexandrakis, K. Lilakos, A. Melidou, N. Stathakis, D. Kyriakou, T. Kourelis (University Hospital of Larisa, Larisa, Greece) |
| 0811 | INFLUENCE OF SERUM FERRITIN LEVELS ON OVERALL SURVIVAL IN PATIENTS WITH MYELODISPLASTIC SYNDROME A. Jerez, A. Fernández, C. Martínez, V. Roldán, M.L. Lozano, M.M. Osma, F. Ortuño, V. Vicente (Hospital Universitario J.M. Morales Meseguer, Murcia, Spain) |
| 0812 | PHOSPHOINOSITIDE-PHOSPHOLIPASE C (PI-PLC) BETA1SIGNALLING IS INVOLVED IN ERYTHROPOIETIN RESPONSE OF LOW RISK MDS PATIENTS C. Finelli, M. Follo, S. Mongiorgi, C. Clissa, F. Chiarini, N. Testoni, M. Baccarani, L. Manzoli, G. Martinelli, A. Martelli, L. Cocco (Institute of Hematology ”Seràgnoli”, Bologna, Italy) |
| 0813 | EFFECT OF AZACITIDINE (AZA) ON TRANSFUSION INDEPENDENCE (TI) AND OVERALL SURVIVAL (OS) IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) J. Seymour, V. Santini, P. Fenaux, A. Giagounidis, G. Sanz, A.F. List, D. McKenzie, J. Backstrom, C.L. Beach (Peter MacCallum Cancer Centre, East Melbourne, Australia) |
| 0814 | EVALUATION OF APOPTOTIC MOLECULAR MARKERS AND GENE METHYLATION STATUS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME E.N. Cortesao, A.C. Gonçalves, M.I. Sousa, C. Moucho, L. Rito, E. Magalhães, A.I. Espadana, M.A. Pereira, A. Teixeira, J. Nascimento Costa, A.B. Sarmento Ribeiro (University Hospital of Coimbra, Coimbra, Portugal) |
ACUTE MYELOID LEUKEMIA - BIOLOGY III
| 0815 | REPRESSION OF THE MYST2 ACETYLTRANSFERASE IN LEUKEMOGENESIS AND ITS ASSOCIATION WITH HEMATOPOIETIC CELL GROWTH |
|---|---|
| 0816 | RADIOIMMUNOTHERAPY USING ANTI-CD33 ANTIBODIES RADIOLABELED WITH THORIUM-226 OR BISMUTH-213 OVERCOME CHEMO- AND RADIORESISTANCE IN MYELOID LEUKEMIA CELLS |
| 0817 | CBL MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML) AND MYELOPROLIFERATIVE NEOPLASMS (MPN) |
| 0818 | CYTOPLASMIC NPM1 DETECTION BY FLOW CYTOMETRY AS SURROGATE FOR THE PRESENCE OF MUTATIONS IN THE NPM1 GENE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA |
| 0819 | EXTENSIVE MUTATIONAL STATUS OF GENES AND CLINICAL OUTCOME IN PEDIATRIC ACUTE MYELOID LEUKEMIA H. Lapillonne, L. Llopis, A. Auvrignon, A. Renneville, M. Labopin, F. Mazingue, C. Perot, J.L. Lai, N. Philippe, P. Ballerini, V. Zurawski, M. Adam, L. Douay, G. Leverger, J. Landman-Parker, C. Preudhomme (Hôpital d'enfants Armand Trousseau, AP-HP and UPMC Univ Paris, UMR S93, Paris, France) |
| 0820 | 'CUP-LIKE' ACUTE MYELOID LEUKEMIA: A REPORT FROM A SINGLE CENTER E. Griva-Kritikou, E. Goumakou, G. Androutsos, V. Xanthopoulos, G. Paterakis, S. Papadhimitriou, A. Agelidis, E. Voukouti, T. Marinakis, G. Gortzolidis, N. Anagnostopoulos, M. Georgiakaki (”G.Gennimatas” District Hospital, Athens, Greece) |
| 0821 | DEFINING T(5;17)(Q22;21) TRANSLOCATION MECHANISM INTHERAPY RELATED AND DE NOVO ACUTE PROMYELOCYTICLEUKEMIA S.K. Hasan, T. Ottone, R. Schlenk, M.E. Mitra, E. Ammatuna, P. Bernasconi, F. Di Raimondo, M.T. Lupo Stanghellini, P. Marco, A.N. Mays, D. Grimwade, H. Dohner, F. Lo-Coco (University Tor Vergata, Rome, Italy) |
| 0822 | SPECIFIC ACTIVITY OF ANTI-CD33 ANTIBODIES RADIOLABELED WITH THORIUM-226 OR BISMUTH-213 PLAYS A CRITICAL ROLE IN EFFICIENT KILLING OF LEUKEMIA CELLS DURING RADIOIMMUNOTHERAPY C. Friesen, M. Roscher, A. Morgenstern, F. Bruchertseifer, K. Abbas, C. Apostolidis, E. Miltner (Institute for Legal Medicine, University Ulm, Ulm, Germany) |
| 0823 | ANGIOGENESIS IN ACUTE PROMYELOCYTIC LEUKEMIA IS MEDIATED BY THE HEPATOCYTE GROWTH FACTOR A. Aires, N.C. Gutiérrez, J.J. Pérez, P. Maiso, E.M. Ocio, M.C. Chillón, F.V. Ticona, L. Díaz, J.F. San Miguel (Servicio de Hematología, Hospital Universitario. Centro de Investigación del Cán, Salamanca, Spain) |
| 0824 | ANALYSIS OF SUBCELLULAR COMPARTMENT EXPRESSION OF SURVIVIN WILD-TYPE AND SPLICING VARIANTS 2B AND DELTAEX3 IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA: IMPACT ON CLINICAL OUTCOME J. Serrano-Lopez, J. Serrano, J. Sanchez-Garcia, L. Hermosin, V. Martin-Palanco, S. Tabares, J. Roman-Gomez, C. Herrera-Arroyo, A. Torres-Gomez (University Hospital Reina Sofia, Codoba, Spain) |
| 0825 | WILMS' TUMOR 1 GENE MUTATIONS ARE ASSOCIATED WITH A HIGHER RISK OF RELAPSE IN YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA FRENCH ASSOCIATION A. Renneville, N. Boissel, V. Zurawski, L. Llopis, V. Biggio, O. Nibourel, N. Philippe, X. Thomas, H. Dombret, C. Preudhomme (CHRU of Lille, Lille, France) |
| 0826 | EVI1 OVEREXPRESSION IS ASSOCIATED WITH UNFAVORABLE SUBTYPES IN PEDIATRIC ACUTE MYELOID LEUKEMIA B.V. Balgobind, S. Lugthart, I.H.I.M. Hollink, T.J.C.M. Arentsen-Peters, E. van Wering, S.S.N. de Graaf, D. Reinhardt, G.J.L. Kaspers, R. Pieters, J. Stary, J. Trka, H.B. Beverloo, M. Zimmermann, R. Delwel, C.M. Zwaan, M.M. van den Heuvel-Eibrink (Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands) |
| 0827 | EXPRESSION OF ANGIOTENSIN-CONVERTING ENZYME (ACE, CD143) AND SHAPERONS (BIP, CALNEXIN, CALRETICULIN) BY LEUKEMIC DENRITIC CELLS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS I. Galtseva, L. Pashin, E. Parovichnikova, A. Sudarikov, S. Danilov, I. Vorobiev, V. Savchenko (National Research Center for Hematology, Moscow, RussianFederation) |
| 0828 | CHARACTERISATION OF A NEW MONOCLONAL ANTIBODY RAISED AGAINST THE MUTANT A OF THE NPM1 PROTEIN: ITS APPLICATION IN THE DIAGNOSIS OF THE NPMC+AML M. Gruszka (European Institute of Oncology, Milan, Italy) |
| 0829 | SURVIVIN EXPRESSION IMPACTS ON SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS J. Greiner, B.A. Guinn, H. Döhner, K.I. Mills, L. Bullinger (University of Ulm, Ulm, Germany) |
| 0830 | HUMAN MYELOID LEUKEMIA BLASTS ARE HIGHLY SENSITIVE TO IRON DEPRIVATION C. Callens, S. Coulon, J. Naudin, N. Boissel, V. Asnafi, R. Monteiro, H. Dombret, E. Macintyre, I. Moura, O. Hermine (Hôpital Necker, Paris, France) |
ACUTE MYELOID LEUKEMIA – CLINICAL II
| 0831 | COMBINATION OF IDARUBICIN, HIGH DOSE CYTARABINE AND SORAFENIB IS HIGHLY EFFECTIVE IN ACHIEVING REMISSION IN NEWLY DIAGNOSED, FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) |
|---|---|
| 0832 | IMPROVED OUTCOME BY ADDITION OF LOMUSTINE (CCNU) TO IDARUBICIN AND CYTARABINE IN ELDERLY PATIENTS WITH DENOVO ACUTE MYELOID LEUKEMIA. A REPORT FROM THE GOELAMS GROUP |
| 0833 | PROLONGED EXPOSURE TO LINTUZUMAB MONOTHERAPY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES - RESULTS OF A PHASE 1 TRIAL |
| 0834 | AS1411 IN COMBINATION WITH CYTARABINE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML) |
| 0835 | CLASSIC II: UPDATED REMISSION DURATION AND SURVIVAL RESULTS OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AND AT LEAST ONE UNFAVORABLE BASELINE PROGNOSTIC FACTOR M Kantarjian, P. Erba, F. Claxton, M.L. Arellano, R.M. Lyons, T.J. Kovacsovics, J. Gabrilove, S. Eckert, S. Faderl (University of Texas MD Anderson Cancer Center, Texas, USA) |
| 0836 | PROGNOSIS OF PATIENTS WITH AML CARRYING 11Q23/MLL RECIPROCAL TRANSLOCATIONS : A RETROSPECTIVE STUDY OF 191 CASES FROM THE FRENCH AML-INTERGROUP A. Banos, A. Jaquet, A. Auvrignon, N. Dastugue, S. Castaigne, G. Michel, P. Fenaux, C. Recher, J. Reiffers, G. Socié, J.L. Harousseau, D. Blaise, B. Lioure, C. Bastard, N. Ifrah, H. Dombret, A. Pigneux (Centre Hospitalier de la Côte Basque, Bayonne, France) |
| 0837 | IMPROVED OUTCOME WITH ANDROGENS AS MAINTENANCE TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AFTER ICL REGIMEN AS INDUCTION THERAPY: RESULTS OF THE GOELAMS SA-2002 MULTICENTER PHASE III RANDOMIZED OPEN TRIAL P. Pigneux, C. Himberlin, M. Hunault-berger, F. Witz, T. Leguay, C. Recher, J.l. Harousseau, B. Lioure, N. Milpied, I. Luquet, M.C. Bene, N. Ifrah, F. Dreyfus, F. Perry, J. Sotto, P. Guardiola (CHU Bordeaux, Pessac, France) |
| 0838 | THE COMBINATION OF FLOW-CYTOMETRY MINIMAL RESIDUAL DISEASE ASSESSMENT AND CYTOGENETIC/GENETIC PARAMETERS ALLOWS A PROPER RISK STRATIFICATION OFADULT AML PATIENTS: IMPLICATION FOR TRANSPLANT CHOICE AND POST CONSOLIDATION THERAPY F. Buccisano, L. Maurillo, M.I. Del Principe, G. Del Poeta, M.A. Irno Consalvo, D. Fraboni, S. Lavorgna, T. Ottone, S. Campagna, E. Ammatuna, M. Rizzo, L. Giannì, M. Postorino, W. Arcese, F. Lo Coco, S. Amadori, A. Venditti (Tor Vergata University Hospital, Rome, Italy) |
| 0839 | PROGNOSTIC AND PREDICTIVE FACTORS FOR SURVIVAL AFTERCOMPLETE REMISSION IN INDUCTION THERAPY OF ACUTE MYELOID LEUKAEMIA M. Pfirrmann, S. Soucek, M. Bornhaeuser, T. Illmer, G. Ehninger, M. Schaich (Ludwig-Maximilians-University, Munich, Germany) |
| 0840 | AMONAFIDE (AS1413) IS UNAFFECTED BY MULTIDRUG RESISTANCE AND IS ASSOCIATED WITH A HIGH RESPONSE RATE IN PATIENTS WITH SECONDARY AML S. Lundberg, M. Chau, H.P. Erba, A.L. Dressel, G. Acton, R.L. Capizzi, M.R. Baer (Antisoma, Cambridge, USA) |
| 0841 | PRE- AND POST-TRANSPLANT FACTORS PREDICT LONG TERM SURVIVAL AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKAEMIA C. Craddock, S. Nagra, N. Duncan, S. Mackinnon, N. Russell (Queen Elizabeth Hospital, Birmingham, United Kingdom) |
| 0842 | MLN823, A NOVEL ORALLY ACTIVE AURORA A KINASE INHIBITOR, IS HIGHLY ACTIVE ALONE AND IN COMBINATION WITH CYTARABINE IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA R. Kelly, R. Swords, D. Mahalingam, S. Nawrocki, E. Medina, S. Smith, S. Padmanabhan, J. Ecsedy, F. Giles, J. Carew (Institute for Drug Development, San Antonio, USA) |
| 0843 | IMPACT OF MYELODYSPLASIA-RELATED CHANGES AS DEFINED BY THE 2008 WHO CLASSIFICATION SYSTEM IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED INTENSIVELY C. Gardin, C. Terré, N. Gachard, I. Tigaud, F. Desangles, C. Bastard, O. Maarek,J.-L. Lai, A. Bernheim, C. Perot, V. Eclache, P. Turlure, X. Thomas, S. Castaigne,M. Michallet, C. Preudhomme, T. Fagot, D. Bordessoule, P. Fenaux,H. Dombret (Hopital Avicenne-APHP, Univ.Paris, Bobigny, France |
| 0844 | FLUDARABINE-BASED INDUCTION THERAPY DOES NOT OVERCOME THE NEGATIVE EFFECT OF ABCG (BCRP) OVEREXPRESSION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS M. Tiribelli, A. Geromin, A. Michelutti, M. Cavallin, A. Candoni, E. Toffoletti, R. Fanin, D. Damiani (Azienda Ospedaliero-Universitaria, Udine, Italy) |
| 0845 | SIX-YEAR OUTCOMES UPDATE FROM A RANDOMIZED PHASE 3TRIAL IN AML: DURABLE EFFECT OF REMISSION MAINTENANCEIMMUNOTHERAPY WITH HISTAMINE DIHYDROCHLORIDE AND LOW-DOSE IL-2 L. Brune, J.M. Rowe, M.E. Buyse, P. Squifflet, S. Castaigne, S.E. Allard, K. Hellstrand (Sahlgrenska Academy, Gothenburg, Sweden) |
| 0846 | CXCR4 AS A PREDICTOR OF RESPONSE IN ACUTE MYELOID LEUKAEMIA M. Giannoccaro, A. Mestice, D. Pastore, A. Liso, M.C. Longo, V. Fesce, C. Ingrosso, N. Sgherza, P. Manduzio, P. Mongelli, R. Angarano, A. Mazzone, V. Liso, G. Specchia (Hematology - University of Bari, Bari, Italy) |
| 0847 | RASGRP1/APTX RATIO STRONGLY CORRELATES WITH CLINICAL RESPONSE AND SURVIVAL IN AML PATIENTS TREATED WITH TIPIFARNIB-BORTEZOMIB COMBINATION S. Paolini, E. Ottaviani, B. Lama, F. Salmi, S. Parisi, C. Clissa, A. Curti, C. Finelli, I. Iacobucci, C. Laterza, C. Papayannidis, P.P. Piccaluga, N. Vianelli, G. Saglio, R. Fanin, F. Morabito, A. Zaccaria, F. Lauria, M. Gobbi, D. Amadori, M. Baccarani, G. Martinelli (University of Bologna, Bologna, Italy) |
| 0848 | IMPACT OF MOLECULAR MARKERS AND CYTOGENETIC ABNORMALITIES ON LONG-TERM OVERALL SURVIVAL AND DISEASE FREE SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS (HSCT) M. Michallet, M. Sobh, F. Barraco, F.E. Nicolini, C. Dumontet, Y. Chelghoum, G. Cannas, E. Nicolas-Virelizier, N. Plesa, S. Ducastelle, J. Troncy, X. Thomas(Edouard Herriot Hospital, Lyon, France) |
| 0850 | THE SAFETY AND EFFICACY OF AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED AND REFRACTORY/RELAPSED AML NOT ELIGIBLE FOR OR RESISTANT TO CHEMOTHERAPY: A MULTICENTERPHASE I/II-STUDY OF THE EAST GERMAN HAEMATOLOGY AND ONCOLOGY STUDY GROUP (OSHO) H.K. Al-Ali (University of Leipzig, Leipzig, Germany) |
CHRONIC MYELOID LEUKEMIA - BIOLOGY & CLINICAL
| 0851 | NILOTINIB SIGNIFICANTLY INDUCES APOPTOSIS IN IMATINIB RESISTANT K562 CELLS, AS EFFECTIVELY AS IN PARENTAL SENSITIVE COUNTERPARTS |
|---|---|
| 0852 | LACK OF KRAS MUTATIONS IN BCR-ABL MUTATION NEGATIVE CML PATIENTS RESISTANT TO FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS |
| 0853 | ACQUIRED IMATINIB RESISTANCE IN CML IS ASSOCIATED WITH TKD MUTATIONS OF BCR-ABL AND/OR ADDITIONAL CHROMOSOMAL ABERRATIONS: CERTAIN TKD MUTATIONS ARE ASSOCIATED WITH CHROMOSOME INSTABILITY |
| 0854 | ROLE OF ABC TRANSPORTERS IN THE DEVELOPMENT OF IMATINIB RESISTANCE |
| 0855 | EIGHTEEN YEARS EXPERIENCE WITH AUTOGRAFTINGFOLLOWED BY IFN-A AND IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). THE GENOA EXPERIENCE A.M. Carella, G. Beltrami, G. Garuti, G. Catania, G. Pica, S. Biasco, S. Nati, A. Congiu, R. Vimercati, E. Rossi, M. Spriano (Divisione di Ematologia , Azienda Ospedaliera Universitaria San Martino, Genova, Italy) |
| 0856 | COMPARISON OF HIGH PREFORMANCE LIQUID CHROMATOGRAPHY- ULTRAVIOLET DETECTION (HPLC-UV) VS LIQUID CHROMATOGRAPHY/ TANDEM MASS SPECTROMETRY (LC/MS/MS) TO DETERMINE IMATINIB PLASMA LEVELS IN CML-CP PATIENTS A. Awidi, I.I. Salem, N. Najib, R. Mefleh, B. Tarawneh (Jordan University, Amman, Jordan) |
| 0857 | NO INHIBITION OF WARFARIN PHARMACOKINETICS AND PHARMACODYNAMICS BY NILOTINIB IN HUMAN SUBJECTS O. Yin, N. Gallagher, D. Fischer, L. Zhao, W. Zhou, G. Golor, H. Schran (Novartis Pharmaceuticals Corporation, Florham Park, USA) |
| 0858 | EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE D. Zackova, H. Klamova, M. Doubek, Z. Pospisil, D. Dvorakova, T. Jurcek,J. Moravcova, K. Machova, J. Rulcova, B. Dobesova, J. Rysava, P. Cetkovsky, F. Razga, J. Mayer (Dept. of Internal Med. and Hemato- Oncology, Univ. Hosp. and Masaryk Univ. Brno, Brno, Czech Republic) |
| 0859 | CHRONIC MYELOID LEUKAEMIA PATIENTS WITH THE E13A2 BCR-ABL TRANSCRIPT HAVE INFERIOR RESPONSE TO IMATINIB THAN E14A2 PATIENTS C.M. Lucas, R.J. Harris, L. Wang, K. Knight, S.J. Watmough, R.E. Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom) |
| 0860 | OVERVIEW OF CHRONIC MYELOID LEUKEMIA AND CURRENT DIAGNOSIS AND TREATMENT PATTERNS FROM 15 HOSPITALS IN CHINA J.X. Wang, Y. Wang, L.G. Qiu, X.J. Huang, B. Jiang, D.P. Wu, A.N. Sun, J.D. Hu, T.B. Liu, T. Liu, H.L. Zhu, Y. Hu, T. Guo, F.Y. Meng, D. Xv, X.Q. Chen, M. Hou, C.Y. Ji, Y. Li, X.Y. Lv, S.J. Wang, L. Jiao, J.M. Wang, H.Y. Ren, L. Yu, F.Y. Chen (Institute of Hematology and Blood Disease hospital,CAMS and PUMC, Tianjin, China) |
| 0861 | CHRONIC MYELOID LEUKEMIA AS SECOND MALIGNANCY; A RETROSPECTIVE MULTICENTRIC STUDY E. Iannitto, V. Minardi, R. Barone, N. Cascavilla, C. Caracciolo,F. Di Raimondo, F. Ferrara, G. Franco, E. Liardo, S. Mancuso, B. Martino, P. Mazza, C. Musolino, M. Musso, P. Musto, G. Pagnucco, F. Palmieri,A. Russo-Rossi, G. Specchia, D. Turri, V. Abbadessa (Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy) |
| 0862 | LONG-TERM FOLLOW-UP AND SAFETY OF DASATINIB IN CML/ALL PH1+ IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USE PROGRAM A. Gozzini, F. Stagno, G. Rege Cambrin, L. Luciano, M. Breccia, E. Abruzzese, G. Martinelli, E. Orlandi, M. Gobbi, P. Pregno, S. Sica, E. Pungolino, E. Angelucci, M. Musso, B. Bruno, S. Galimberti, R. Nieddu, G. Specchia, M.G. Kropp, M. Annunziata, P. Musto, M. Cervellera, A.M. Carella, M. Pini, F. Radaelli, V. Meneghini, D. Russo, E. Montefusco, R. Marasca, G. Gaidano (AUO Careggi, Firenze, Italy) |
| 0863 | EFFECT OF THE PROTON PUMP INHIBITOR ESOMEPRAZOLE ON THE ORAL ABSORPTION AND PHARMACOKINETICS OF NILOTINIB O. Yin, N. Gallagher, D. Fischer, E. Demirhan, W. Zhou, G. Golor, H. Schran (Novartis Pharmaceuticals Corporation, Florham Park, USA) |
| 0864 | IMATINIB TREATMENT IN ELDERLY PATIENTS (>65 YEARS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE R. Latagliata, M. Breccia, I. Carmosino, M. Mancini, D. Diverio, R. De Cuia, L. Cannella, C. Stefanizzi, L. Napoleone, P. Volpicelli, F. Vozella, G. Alimena (Ematologia - Università “La Sapienza”, Rome, Italy) |
| 0865 | EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR - INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS Z. Shen, X. Huang, F. Meng, J. Wang, T. Liu, J. Hu, J. Wang, Y. Zhao,R. Woodman, P. Zou (Shanghai Jiao Tong University School of Medicine, Shanghai, China) |
| 0866 | PROANGIOGENIC CYTOKINES IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB MESYLATE K. Kotlyarchuk, L. Lukavetsky, O. Danysh, A. Lukjanova, M. Kolisnyk, Z. Maslyak (SI “Institute of Blood Pathology and Transfusion Medicine, UAMS”, Lviv, Ukraine) |
| 0867 | IMATINIB DOSE ESCALATION FOR CML RESISTANT PATIENTS IS USEFUL IN GENERAL PRACTICE: IMPACT ON CYTOGENETIC REMISSION Yu Zaritskey (Centre of Heart, Blood & Endocrinology, St Petersburg, Russian Federation) |
MYELOPROLIFERATIVE DISORDERS - BIOLOGY
| 0868 | IDENTIFICATION OF A NOVEL MODE OF KINASE INHIBITOR RESISTANCE: AN F604S EXCHANGE IN FIP1L1-PDGFRA MODULATES FIP1L1-PDGFRA PROTEIN STABILITY IN A SRC-DEPENDENT MANNER |
|---|---|
| 0870 | MIR-28 EXPRESSION IN PLATELETS OF MYELOPROLIFERATIVE PATIENTS VIA STAT5 CONSTITUTIVE ACTIVITY |
| 0871 | JAK2V617F-INDEPENDENT OVEREXPRESSION OF AUTOCRINE/ PARACRINE HEPATOCYTE GROWTH FACTOR (HGF) AND/ORINTERLEUKIN-1 (IL-11) IN POLYCYTHEMIA VERA AND INHIBITIONOF CLONAL EYTHROID PROGENITOR GROWTH BY BLOCKING THE HGF/IL-11 PATHWAYS |
| 0872 | CIRCULATING ENDOTHELIAL COLONY-FORMING CELLS ARE INCREASED IN PATIENTS WITH PRIMARY MYELOFIBROSIS, DO NOT BEAR THE JAK-2V617F MUTATION, AND COEXIST WITH JAK-2V617F-POSITIVE MATURE ENDOTHELIAL CELLS |
| 0873 | CIAP-1 AND CIAP-2 ANTI-APOPTOTIC MOLECULES ARE OVEREXPRESSED IN ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS R. Tognon, E.P.L. Gasparotto, A.F. Ferreira, R.C.V. Carrara, S. Kashima, D.T. Covas, M. Santana, E.X. Souto, M.A. Zanichelli, C.E.E. Velano,B.P. Simões, A.M. Souza, F.A. Castro (Faculdade de Ciências Farmacêuticas de Ribeirão Preto/University of São Paulo, Ribeirao Preto, Brazil) |
| 0874 | GENE EXPRESSION PROFILING OF CD34+ CELLS IN MYELOPROLIFERATIVE DISORDERS BY CDNA MICROARRAY TECHNOLOGY P. Cokic, J. Han, S. Mojsilovic, B. Beleslin-Cokic, K. Mirkovic, N. Kraguljac- Kurtovic, S. Damjanovic, M. Gotic, R. Skoda, R. Puri, C. Noguchi, A. Schechter (Institute for Medical Research, Belgrade, Serbia) |
| 0875 | THREE NOVEL MUTATIONS IN THE PROLYL HYDROXYLASE DOMAIN PROTEIN 2 GENE OF THE OXYGEN SENSING PATHWAY IN PATIENTS WITH ISOLATED ERYTHROCYTOSIS E. Albiero, M. Ruggeri, S. Fortuna, S. Finotto, D. Madeo, M. Bernardi, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy) |
| 0876 | REACTIVE OXYGEN SPECIES ARE DIFFERENTIALLY REGULATEDIN CHRONIC MYELOID LEUKEMIA VERSUS PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS E. Guerin (CHU, Pessac, France) |
| 0877 | TYROSINE PHOSPHORYLATED SOCS3 IS UNABLE TO REGULATETHE MYELOPROLIFERATIVE NEOPLASM ASSOCIATED- JAK2 V617F KINASE J. Elliott, Y. Suessmuth, K. Nahlik, M.F. McMullin, S. Constantinescu, J.A. Johnston (Queens University Belfast, Belfast, United Kingdom) |
| 0878 | A ROLE FOR TIF1GAMMA IN CHRONIC MYELOMONOCYTIC LEUKAEMIA R. Aucagne, L.D. Delva (Inserm U86, Dijon, France) |
| 0879 | A NEW PROLYL HYDROXYLASE DOMAIN PROTEIN 2 MUTATION IN A JAK2(V617F) POSITIVE PATIENT WITH A FAMILIAL MYELOPROLIFERATIVE DISEASE E. Albiero, M. Ruggeri, S. Finotto, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy) |
| 0880 | SOCS, SOCS3 AND PTPN6 METHYLATION IN PATIENTS WITH PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE DISEASES (CMPD) M. Foedermayr, M. Huber, H. Hauser, A. Weltermann, O. Zach, D. Lutz (Elisabethinen Hospital, Linz, Austria) |
| 0881 | AME AFFECTS MEGAKARYOCYTIC DIFFERENTIATION AND INCREASES PRO-PLATELATS FORMATION IN VITRO C.R. Rinaldi, V. Senyuk, P. Rinaldi, G Nucifora, F. Pane, B. Rotoli (Federico II University, Naples, Italy) |
| 0882 | CONTRIBUTION OF BONE MARROW DERIVED CELL ANGIOGENESIS IN BCR/ABL NEGATIVE CHRONIC MYELOPROLIFERATIVE DISEASE G. Gritti, U. Gianelli, S. Lonati, I. Silvestris, C. Vener, L. Boiocchi, A. Freyrie, A. Cortelezzi, G. Lambertenghi (IRCCS Foundation “Policlinico Mangiagalli and Regina Elena”, Milan, Italy) |
| 0883 | STUDY OF MEGAKARYOPOIESIS AND PROPLATELET FORMATION IN PRIMARY MYELOFIBROSIS A. Balduini, S. Badalucco, M. Massa, V. Rosti, G. Barosi (Department o Biochemistry, University of Pavia, Pavia, Italy) |
| 0884 | MURINE MYELOPROLIFERATIVE DISORDER WITH LIVER LESION: CHARACTERISTICS OF LEUKEMIA STEM CELLS AND PHENOTYPE OF CELLS INVADED LIVER A.E. Bigildeev, I.N. Shipounova, D.A. Svinareva, N.J. Drize (Hematology Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation) |
| 0885 | EPIGENETIC CHANGES IN JAK2V617F POSITIVE MYELOPROLIFERATIVE DISORDERS A. Uras, M.A. Fancello, M. Monne, G. Piras, A.D. Palmas, E. Gaviano, A. Noli, A. Bianchi, A. Gabbas (San Francesco Hospital, Nuoro, Italy) |
| 0886 | PRIMARY MYELOFIBROSIS CD34+ CELLS SHOW DIFFERENT CXCR4 CHEMOKINE RECEPTOR PROFILES AT SITES OF DISEASE ACTIVITY M. Massa, R. Campanelli, V. Rosti, E. Bonetti, E. Moretti, L. Villani, S. Lo Pò, G. Barosi (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) |
| 0887 | IDIOPATHIC HYPEREOSINOPHILIC SYNDROME IN CHILDRENMOLECULAR ANALYSIS AND CLONAL EVOLUTION M.C. Rapanotti, R. Caruso, S. Zaza, M.D. Divona, L. Trotta, G. Federici, S. Amadori, G. De Rossi, F. Lo Coco (Policlinico Tor Vergata -University of Rome, Rome, Italy) |
DEVELOPMENTAL HEMATMYELOPROLIFERATIVE DISORDERS - BIOLOGY & CLINICAL
| 0888 | CONSISTENT UP-REGULATION OF STAT3 INDEPENDENTLY OF JAK2 MUTATIONS IN A NEW MURINE MODEL OF ESSENTIAL THROMBOCYTHEMIA |
|---|---|
| 0889 | ELEVATED PRV-1 PLASMA LEVEL IS A RISK FACTOR FOR TRANSIENT ISCHEMIC ATTACK (TIA) IN ESSENTIAL THROMBOCYTHEMIA (ET) |
| 0890 | INCREASED EXPRESSION OF THE ATP9A GENE IN ESSENTIAL |
| 0891 | SOCS3 TYROSINE PHOSPHORYLATION AS A BIO-MARKER FOR THE MYELOPROLIFERATIVE DISORDER-ASSOCIATED MUTANT JAK2 KINASES |
| 0892 | CONCURRENT JAK2 V617F MUTATION AND BCR-ABL REARRANGEMENT IN A ESSENTIAL THROMBOCYTHEMIA PATIENT E Novella, M. Bernardi, F. Pomponi, E. Peotta, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy) |
| 0893 | NATURAL EVOLUTION OF JAK2V617F ALLELE BURDEN IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA PATIENTS NOT RECEIVING CYTOREDUCTIVE TREATMENT C. Besses, A. Alvarez-Larran, L. Martínez-Avilés, R. Longarón, S. Serrano, B. Bellosillo (Hospital del Mar, Barcelona, Spain) |
| 0894 | POLYCYTHEMIA VERA (PV) BUT NOT ESSENTIAL THROMBOCYTHEMIA (ET) REDUCES THE LIFE EXPECTANCY IN ELDERLY F. Tezza, E. Ruzzon, S. Zambon, E. Manzato, F. Fabris, M.L. Randi (University of Padua, Medical School, Padua, Italy) |
| 0895 | ANALYSIS OF BONE MARROW PATHOLOGY, ANGIOGENESIS AND CLINICAL PARAMETERS IN PATIENTS WITH PHILADELPHIANEGATIVE MYELOPROLIFERATIVE DISORDERS A.G. Zhelyazkova, L.T. Gercheva, P. Kolova, B. Tonchev (Varna University of Medicine, Varna, Bulgaria) |
| 0896 | THY-, C-KIT AND TFR EXPRESSIONS ON CD34+ MYELOBLASTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND THEIR RELATIONS TO IPSS M. Atfy (Hospital of Zagazig University, Zagazig, Egypt) |
| 0897 | LANGERHANS CELL HISTIOCYTOSIS IN CHILDREN - DIAGNOSIS, TREATMENT AND FOLLOW-UP S. Glamocanin, O. Muratovska, K. Martinova, Z. Trajkova-Antevska, B. Conevska, S. Koceva, G. Petrusevska (University Children's Hospital, Skopje, Macedonia) |
| 0898 | THROMBOSIS IN POLYCYTHEMIA VERA (PV) ARE LIKELY TBE RELATED TO HIGHER JAK2V617F ALLELE BURDEN I. Bertozzi, M. Scapin, F. Tezza, R. Scandellari, F. Fabris, M.L. Randi (University of Padua, Medical School, Padua, Italy) |
| 0899 | LEUKOCYTOSIS IS A RISK FACTOR FOR RECURRENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA V. De Stefano, T. Za, E. Rossi, A.M. Vannucchi, M. Ruggeri, E. Elli, C. Micò, A. Tieghi, R. Cacciola, C. Santoro, G. Gerli, N. Vianelli, P. Guglielmelli, L. Pieri, F. Scognamiglio, F. Rodeghiero, E.M. Pogliani, G. Finazzi, L. Gugliotta, G. Leone, T. Barbui (Institute of Hematology, Catholic University, Rome, Italy) |
CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS -
BIOLOGY II
| 0900 | EVALUATION OF ZAP-70 EXPRESSION BY MEAN FLUORESCENCE INTENSITY T/B RATIO IS A MORE USEFUL PREOGNOSTICATORTHAN PERCENTAGE OF POSITIVE CELLS IN CHRONIC LYMPHOCITIC LEUKEMIA (CLL) |
|---|---|
| 0901 | MALDI-TOF MS PROFILING TO EXAMINE THE PROTEIN CONTENT IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA |
| 0902 | CHARACTERIZATION OF 22Q11 DELETION IN CLL PATIENTS |
| 0903 | IDENTIFICATION OF PEPTIDE SEQUENCES BINDIN SPECIFICALLY TO THE BCR OF B-CLL CELLS |
| 0904 | HEAT SHOCK PROTEIN 2 (HSP27) GENE-EXPRESSION: A NOVE PROGNOSTIC MARKER IN CLL E. Reiter, M. Gruber, E. Porpaczy, T. Le, B. Hilgarth, M. Bilban, D. Heintel, K. Eigenberger, C. Skrabs, A. Hauswirth, I. Schwarzinger, H. Esterbauer, E. Krömer, C. Fonatsch, A. Gaiger, U. Jäger, K. Vanura (Department of Internal Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria) |
| 0905 | QUANTITATIVE ANALYSIS OF REPETITIVE ELEMENT METHYLATION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA A Fabris, V. Motta, V. Bollati, V. Pegoraro, G. Cutrona, L. Mosca, S. Matis,D. Ronchetti, M. Colombo, M. Gentile, M. Spriano, V. Callea, G. Festini,S. Molica, A. Cortelezzi, G. Lambertenghi Deliliers, F. Morabito, M. Ferrarini,P.A. Bertazzi, A. Baccarelli, A. Neri (Università di Milano, Fondazione IRCCS Policlinico, Milano, Milan, Italy) |
| 0906 | CHRONIC LYMPHOCYTIC LEUKEMIA CELLS RESCUE THEMSELVES BY INCREASING THE ANTI-APOPTOTIC EFFECT OF BONE MARROW STROMA M. Plander, S. Seegers, P. Ugocsai, S. Schwarz, E. Orsó, J. Ivanyi, G. Brockhoff (County Hospital of Vas, Szombathely, Hungary) |
| 0907 | RELATIONSHIP BETWEEN THERAPY AND CLONAL EVOLUTION OF TP53 ABNORMALITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA J. Malcikova, J. Smardova, P. Kuglik, Y. Brychtova, M. Doubek, J. Kotaskova, B. Tichy, S. Pospisilova, J. Mayer, M. Trbusek (University Hospital Brno and Medical Faculty of Masaryk University Brno, Brno, Czech Republic) |
| 0908 | IGVH MUTATION STATUS AND ZAP-70 EXPRESSION AS INDICATORS FOR MOLECULAR PROFILING SIGNATURE IN B-CLL PATIENTS FOR PROGNOSTIC CLASSIFICATION A. Trojani, B. Di Camillo, A. Tedeschi, M. Lodola, C. Colombo, F. Ricci,S. Veronese, B. Scarpati, E. Morra, M. Montillo (Ospedale Niguarda Cà Granda, Milan, Italy) |
| 0909 | SENSITIZATION OF LEUKEMIC CELLS TO FLUDARABINE BY MONOCLONAL ANTIBODY RITUXIMAB - IDENTIFICATION OF RESPONSIBLE GENES L. Rocnova, B. Tichy, S. Cejkova, D. Potesil, Y. Brychtova, S. Pospisilova, J. Mayer, M. Trbusek (University Hospital and Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic) |
| 0910 | THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS S. Herter, I. Del Giudice, C. Schmidt, T. Fauti, C Klein, P. Umana, M.J.S. Dyer, R. Foa, R. Grau (Glycart Biotechnology AG, Schlieren, Switzerland) |
| 0911 | IN VITRO CYTOTOXICITY AND ZNF331 ARE RELATED TO RESPONSE AND RELAPSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH FLUDARABINE,CYCLOPHOSPHAMIDE AND MITOXANTRONE (FCM) N. Villamor, D. Colomer, F. Bosch, A. Ferrer, M. Aymerich, S. Marce, P. Jares, E. Montserrat, E. Campo (Hospital Clínic de Barcelona, Barcelona, Spain |
| 0912 | EFFECT OF ZAP-70 ON MIRNA EXPRESSION PROFILE IN CLL V. Pede, J. Philippé, P. Mestdagh, J. Vandesompele, B. Verhasselt (Ghent University Hospital, Ghent, Belgium) |
| 0913 | ZAP-70 HAS HIGHER EXPRESSION IN LYMPH NODES AND BONE MARROW COMPARED TO PERIPHERAL BLOOD IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) O. Jaksic, B. Gizdic, T. Stoos Veic, Z. Miletic, R. Kusec, K. Trutin Ostovic, V. Pandzic Jaksic, V. Pejsa, B. Jaksic (Dubrava University Hospital, Zagreb, Croatia) |
| 0914 | THE DISTRIBUTION OF XRCC1-399 AND XPD-751 GENOTYPESIN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH SECONDARY TUMORS AND RICHTER TRANSFORMATION N. Bilous, I. Abramenko, A. Chumak, A. Kostin, Z. Martina, I. Dyagil, I. Kryachouk, I. Filonenko, N. Yuschenko (Research Centre for Radiation Medicine, Kiev, Ukraine) |
| 0915 | WHAT IS THE ROLE OF BONE MARROW PATHOLOGICAL EXAMINATION IN CLL? EXTENSIVE HISTOLOGICAL, IMMUNOHISTOCHEMICAL AND MOLECULAR EXAMINATION IN A SERIES OF 137 PATIENTS M. Fameli, N. Stavroyianni, G. Kannellis, E. Pouliou, C. Lalayanni, R. Saloum, A. Fassas, A. Anagnostopoulos, K. Stamatopoulos, T. Papadaki (Evangelismos Hospital, Athens, Greece) |
| 0916 | CLLU1 GENE EXPRESSION LEVELS PREDICTS VH MUTATIONAL STATUS IN 90% OF CLL PATIENTS G. Georgiou, M. Roumelioti, D. Palaiologou, V. Mpartzi, A. Markopoulos, G. Stravodimos, M. Dimou, A. Efthymiou, L. Petrikos, T. Vassilakopoulos, M. Aggelopoulou, C. Kyrtsonis, P. Panayiotidis (University of Athens, Athens, Greece) |
| 0917 | CD72 EXPRESSION PATTERNS IN ZAP70 POSITIVE AND NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA: DIFERENTIAL EXPRESSION OF GENES RELATED WITH BCR SIGNALLING F.P. de Paula Careta, R.A. Panepucci, D.M.M Mattos, R. Proto-Siqueira, F.S. Araújo, A.B. Garcia, A.G. Araújo, W. Silva |
| 0918 | DIFFERENT CXCR, CXCR, CXCR, CCR7 AND KI-67 EXPRESSION IN PERIPHERAL BLOOD, BONE MARROW AND LYMPH NODES IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) O. Jaksic, B. Gizdic, T. Stoos Veic, M. Pirsic, R. Kusec, V. Pandzic Jaksic, B. Jaksic, V. Pejsa (Dubrava University Hospital, Zagreb, Croatia) |
CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS -
CLINICAL II
| 0919 | HIGH ACTIVITY OF SINGLE-AGENT OFATUMUMAB, A NOVEL CD20 MONOCLONAL ANTIBODY, IN FLUDARABINE- AND ALEMTUZUMABREFRACTORY OR BULKY FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, REGARDLESS OF PRIOR RITUXIMAB EXPOSURE |
|---|---|
| 0920 | MULTICENTER EXTERNAL VALIDATION OF A NOMOGRAM AND A SCORE FOR PREDICTING OVERALL SURVIVAL IN CLL: A STUDY ON 757 PATIENTS |
| 0921 | THE PROGNOSIS OF CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKAEMIA AND IS RECAPITULATED BY BIOLOGICAL RISKFACTORS |
| 0922 | SUCCESSFUL TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA SHOWING 17P DELETION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND ALEMTUZUMAB |
| 0923 | LOW DENSITY LIPOPROTEIN RECEPTOR PROTEIN (LRP4) RS2306029SINGLE NUCLEOTIDE POLYMORPHISM PREDISPOSES TO TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME D. Rossi, S. Rasi, A. Bruscaggin, A. Puma, E. Sozzi, V. Gattei, F. Lauria, F. Forconi, G. Gaidano (Division of Hematology, Amedeo Avogadro University, Novara, Italy) |
| 0924 | A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA C.M. Wendtner, D. Mahadevan, S. Coutré, P. Hillmen, S. Stilgenbauer, O. Frankfurt, A. Bloor, F. Bosch, R. Furman, L. Uharek, E. Kimby, M. Gobbi, L. Dreisback, D. Hurd, M. Sekeres, J. Gribben, S. Shah, L. Moutouh-de Parseval, A. Chanan-Khan (University of Cologne, Cologne, Germany) |
| 0925 | RELATIONSHIP BETWEEN CYTOGENETIC ANOMALIES AND BIOMARKERS IN BINET STAGE A PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1 GISL STUDY A Fabris, G. Cutrona, M. Gentile, S. Matis, E.A. Pesce, F. Di Raimondo, A. Musolino, M. Gobbi, N. Di Rienzo, F.R. Mauro, R. Cantaffa, M. Brugiatelli, F. Merli, S. Zupo, C. Mammi, L. Baldini, F. Angrilli, G. Quintana, U. Consoli, G. Bertoldero, E. Iannitto, P. Di Tonno, A. Fragasso, S. Molica, P. Musto, M.C. Cox, G. Festini, V. Callea, S. Sacchi, A. Cortelezzi, G. Lambertenghi Deliliers (Università di Milano, Fondazione IRCCS Policlinico, Milan, Italy) |
| 0926 | BETA2-MICROGLOBULIN IS A BETTER PREDICTOR OFTREATMENT-FREE SURVIVAL IN PATIENTS WITH CHRONICLYMPHOCYTIC LEUKAEMIA IF ADJUSTED ACCORDING TO GLOMERULAR FILTRATION RATE J. Delgado, G. Pratt, N. Phillips, J. Briones, C. Fegan, J. Nomdedeu, C. Pepper, A. Aventin, R. Martino, D.W. Milligan, J. Sierra (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain) |
| 0927 | FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OFCZECH CLL STUDY GROUP L. Smolej, D. Lysak, T. Papajik, J. Salkova, M. Brejcha, V. Vozobulova,J. Karban, M. Hrudkova, E. Cmunt, P. Turcsanyi, A. Jungova, H. Krejcova, M. Trneny (University Hospital and Medical School, Hradec Kralove, Czech Republic) |
| 0928 | LENALIDOMIDE ASSOCIATED TUMOR FLARE REACTION CORRELATES WITH CLINICAL RESPONSE IN PATIENTS WITHRELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) T. Sher, K. Miller, M. Patel, A. Whitworth, L. Musial, D. Lawrence, S. Padmanabhan, S. Ailawadhi, G. Wilding, D. DePaolo, N. Bangia, M.S. Czuczman, P.K. Wallace, K.P. Lee, A. Chanan Khan (Roswell Park Cancer Institute, Buffalo, USA) |
| 0929 | ABNORMAL SERUM FREE LIGHT CHAIN RATIO AS A PREDICTOR OF ADVERSE OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA : HAS THE TIME COME FOR A SIMPLE PROGNOSTIC MARKER? Z.A. Yegin, M. Yagci, Z.N. Özkurt, N. Kursunoglu, S.Z. Aki (Gazi University Faculty of Medicine, Ankara, Turkey) |
| 0930 | HIGH INTRACELLULAR CONTENT OF CYCLIN-DEPENDENT KINASE INHIBITOR P27KIP1 IN EARLY- AND INTERMEDIATE STAGE B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA LYMPHOCYTES PREDICTS RAPID PROGRESSION OF THE DISEASE L. Ciszak, D. Wolowiec, M. Wojtowicz, A. Kosmaczewska, S. Potoczek, D. Urbaniak-Kujda, K. Kapelko-Slowik, K. Kuliczkowski, I. Frydecka (Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland) |
| 0931 | ALEMTUZUMAB ADMINISTERED BY SUBCUTANEOUS ROUTE IS LESS EFFECTIVE THAN INTRAVENOUS ROUTE FOR FIRST LINETHERAPY OF T-CELL PROLYMPHOCYTIC LEUKAEMIA: RESULTS OF A PILOT STUDY (UKCLL05) E. Matutes, A. Khot, A . Kaczmarek, M. Ethell, M. Hamblin, A. Roy, E. Grand, C. Dearden (Royal Marsden Hospital, London, United Kingdom) |
| 0932 | INCLUSION OF TOTAL BODY CT SCAN IN THE INITIAL WORK-UP OF CLL PATIENTS WITH EARLY-STAGE ON CLINICAL GROUNDS: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1- GISL STUDY M. Gentile, G. Cutrona, S. Fabris, E. Pesce, F. Di Raimondo, N. Di Renzo,F.R. Mauro, R. Cantaffa, M. Brugiatelli, F. Merli, L. Baldini, G. Quintana,E. Iannitto, P. Di Tonno, A. Fragasso, S. Molica, V. Callea, S. Sacchi,M. Federico, A. Neri, M. Ferrarini, F. Morabito (U.O. Ematologia Ospedale Civile dell’Annunziata di Cosenza, Italy, Cosenza, Italy) |
| 0933 | CLL WITH BURKITT-TYPE TRANSLOCATION: A SUBGROUP WITH AN AGGRESSIVE DISEASE COURSE N. Put, K. Rack, A. Janssens, P. Meeus, C. Barin, A. Delannoy, V. Eclache, M. Janssen, F. Nguyen-Khac, I. Radford-Weiss, A. Van Hoof, J. Verschuere, E. Wouters, W. Wynendaele, I. Wlodarska, P. Vandenberghe, L. Michaux (UZ Leuven, Leuven, Belgium) |
MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY II
| 0934 | AN EXPERIMENTAL STUDY FOR PERIPHERAL NEUROPATH ASSOCIATED WITH WALDENSTRÖM'S MACROGLOBULINEMIA* |
|---|---|
| 0935 | HGF AND IGF-1 POTENTIATE SDF-1 MEDIATED MYELOMA CELL MIGRATION THROUGH ACTIVATION OF PAK |
| 0936 | SPARC GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS AND ITS REGULATION BY CYTOTOXIC TREATMENTS IN MYELOMA CELL LINES |
| 0937 | GLOBAL MICRORNA EXPRESSION PROFILING IN MULTIPLE MYELOMA IDENTIFIES DEREGULATED PATTERNS ASSOCIATED WITH DISTINCT MOLECULAR GROUPS |
| 0938 | THE COMPARISON OF SERUM LEVELS OF SELECTED BIOMARKERS AND CYTOGENETIC CHANGES IN MULTIPLE MYELOMA T. Pika, J. Balcarkova, M. Holzerova, J. Minarik, M. Budikova, K. Langova, J. Bacovsky, M. Jarosova, V. Scudla (University Hospital, Olomouc, Czech Republic) |
| 0930 | NON-PROTEASOME TARGETS OF PROTEASOME INHIBITORS BORTEZOMIB AND CARFILZOMIB S. Arastu-Kapur, K.D. Shenk, C.J. Kirk, D. Swinarski, T. Muchamuel, M.K. Bennett, F. Parlati (Proteolix, South San Francisco, USA) |
| 0940 | CXCR4 AND CD43 CO-EXPRESSION IN PLASMA CELL MALIGNANCIES S. Improta, A. Lucania, M.R. Villa, P. Della Cioppa, M. Esposito, A.A. Quirino, L. Mastrullo (ASL NA1 San Gennaro, Naples, Italy) |
| 0941 | NOVEL WHOLE CELL ASSAYS TO MONITOR PROTEASOME ACTIVITY IN MULTIPLE MYELOMA A. Liggett, T.C. Morris, B. Walker, A.E. Irvine (Queen's University Belfast, Belfast, Northern Ireland) |
| 0942 | GROWTH FACTORS, HGF, IL-, AND IL-3 DIFFERENTIALLY REGULATE DIFFERENTIATION OF HUMAN MULTIPLE MYELOMA MESENCHYMAL STEM CELLS IN RELATION TO BONE METABOLISM J. Park, K.-S. Ahn, C. Lee, E.-K. Bae, B.-S. Kim, S.-M. Bang, I. Kim, D.-S. Lee, S. Park, B.-K. Kim, S.-S. Yoon (Seoul National University, College of Medicine, Cancer research institute, Seoul, South-Korea) |
| 0943 | IMMUNOHISTOCHEMICAL EVALUATION OF SARCOGLYCANS AND INTEGRIN IN GINGIVAL EPITHELIUM OF MULTIPLE MYELOMA PATIENTS WITH BISPHOSPHONATE-INDUCED OSTEONECROSIS OF THE JAW A. Allegra, S. Russo, A. Cannavò, A. Alonci, G. Oteri, A. Favaloro, E. Nastro, F.S. De Ponte, D. Cicciù, G. Anastasi, C. Musolino (Division of Hematology, Messina, Italy) |
| 0944 | SEQUENTIAL EVALUATION OF SERUM HEPCIDIN IN ANEMIC MYELOMA PATIENTS: A PILOT STUDY OF CORRELATIONS WITH MYELOMA TREATMENT, DISEASE VARIABLES, AND ANEMIA RESPONSE E. Katodritou, T. Ganz, E. Verrou, O. Olbina, E. Terpos, V. Gastari, C. Hadjiaggelidou, S. Georgiadou, M. Varthaliti, A. Polyzopoulos, S. Zlatintsi,N. Constantinou, M. Westerman, K. Zervas (Theagenio Cancer Center, Thessaloniki, Greece) |
| 0945 | FGFR3 IS EXPRESSED AND IMPORTANT FOR SURVIVAL IN INA-, A HUMAN MYELOMA CELL LINE WITHOUT A T(4;14) T.K. Våtsveen, A.T. Brenne, H.Y. Dai, A. Sundan, A. Waage, M. Børset (NTNU, Trondheim, Norway) |
| 0946 | ESTABLISHMENT OF AN INTERLEUKIN-6 INDEPENDENT VARIANT (CMA-03/06) OF THE HUMAN MYELOMA CELL LINE CMA-03:BIOLOGICAL AND MOLECULAR CHARACTERIZATION BY A GENOMIC INTEGRATIVE ANALYSIS D. Verdelli, L. Nobili, K. Todoerti, L. Mosca, S. Fabris, G. Lambertenghi Deliliers, L. Lombardi, A. Neri (Dip Sc. Mediche, Centro Leucemie, Università Milano, Fond. IRCCS Policlinico, Milan, Italy) |
| 0947 | INHIBITION OF PROTEASOME SUBUNITS BY CARFILZOMIB IN PHASE 1B CLINICAL TRIAL MEASURED USING A NOVEL SUBUNIT-SPECIFIC ELISA Q Levitsky, S.J. Lee, K.D. Shenk, S. Arastu-Kapur, M.K. Bennett, F. Parlati (Proteolix Inc, South San Francisco, USA) |
| 0948 | EXPRESSION OF CD27 ON PLASMA CELLS IN MULTIPLE MYELOMA L. Kovarova, I. Buresova, K. Muthu Raja, M. Penka, R. Hajek (University Hospital, Brno, Czech Republic) |
MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL II
| 0949 | LONGER DURATION OF TREATMENT AND MAINTENANCE OF BEST RESPONSE WITH LENALIDOMIDE + DEXAMETHASONE INCREASES OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
|---|---|
| 0950 | CONFIRMATION OF THE UTILITY OF THE IMWG THROMBOPROPHYLAXISSTRATEGY IN MYELOMA PATIENTS RECEIVING THALIDOMIDE; EXPERIENCE OF A LARGE SINGLE CENTRE INSTITUTION |
| 0951 | CLINICAL EFFICACY OF VEL-CTD (BORTEZOMIB, CYCLOPHOSPHAMIDE, THALIDOMIDE, AND DEXAMETHASONE) REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE II STUDY |
| 0952 | OPTIMIZATION OF BORTEZOMIB-BASED COMBINATIVE REGIMEN IN ELDERLY RELAPSED MULTIPLE MYELOMA PATIENTS |
| 0953 | EFFICACY OF PAD REGIMEN AS AN INDUCTION THERAPY BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN VAD OR CTD REFRACTORY MYELOMA M. Kraj, K. Warzocha, R. Poglód, B. Kwasniak, B. Ceglarek (Institute of Hematology and Transfusion Medicine, Warsaw, Poland |
| 0954 | INCORPORATION OF THE BONE MARKER CARBOXY-TERMINAL TELOPEPTIDE OF TYPE-1 COLLAGEN (ICTP) INTO A COMBINEDISS-ICTP SCORE IMPROVES THE PROGNOSTIC SIGNIFICANCE OFTHE ISS IN SYMPTOMATIC MULTIPLE MYELOMA C. Jakob, J. Sterz, P. Liebisch, U. Heider, M. Kaiser, M. Mieth, C. Müller, O. Sezer (Charité - Universitätsmedizin Berlin, Berlin, Germany) |
| 0955 | A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, +PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSEDELDERLY PATIENTS WITH MULTIPLE MYELOMA S. Sacchi, R. Marcheselli, S. Pozzi, A. Bari, O. Ciarcia, L. Masini, A. Lazzaro, F. Morabito, A. Fragasso, N. Di Renzo, G. Quarta, G. Buda, P. Musto, M.L. Vigliotti, A. Pastorini, M. Brugiatelli (Universita di Modena, Modena, Italy) |
| 0956 | SURVIVAL ANALYSIS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM REPORT FROM AN INTERNATIONAL ELECTRONIC OBSERVATIONAL STUDY OF BORTEZOMIB M. Delforge, H. de Samblanx, K. Zervas, E. Katodritou, D. Sargin, C. Hulin, L. Ahlberg, J. de la Rubia, K. Abdulkadyrov, R. Ganguly, J. Diels, R. Dhawan (University Hospital Leuven, Leuven, Belgium) |
| 0957 | THALIDOMIDE OR BORTEZOMIB IN COMBINATION WITHDEXAMETHASONE AS SECOND-LINE THERAPY FOR REFRACTORY/ RELAPSED MULTIPLE MYELOMA: A COMPARISON OF EFFICACY AND TOXICITY M. Varettoni (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) |
| 0958 | INCREASED BONE MINERAL DENSITY IN A SUBSET OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO RECEIVED THE COMBINATION OF BORTEZOMIB, DEXAMETHASONE ANDZOLEDRONIC ACID E. Terpos, D. Christoulas, P. Kokkoris, M. Gavriatopoulou, G. Boutsikas,M. Migkou, K. Anargyrou, E. Kastritis, K. Tsionos, M.A. Dimopoulos (University of Athens School of Medicine, Athens, Greece) |
| 0959 | COMBINATION OF INTERNATIONAL STAGING SYSTEM AND CYTOGENETICS CAN PREDICT POOR PROGNOSIS IN MULTIPLE MYELOMA AFTER HD-CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION E. Tóthová, A. Kafková, N. Stecová, E. Sˇ vorová, K. Fiedlerová, M. Soska (UPJSˇ and University hospital L. Pasteur, Kosˇ ice, Slovakia) |
| 0960 | THE IMPACT OF FRONTLINE TREATMENT ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA: THE SGH EXPERIENCE Z.T. Lao, W.C.N. Wee, Y.S. Lee, S. Su Su, H.C. Wee, A.Q.C. Choo, P. Colin, A.L. Ang, C.Y. Yiu, D. Tan, L.S. Kam (Singapore Health Services/SingaporeGeneral Hospital, Singapore, Singapore) |
| 0961 | 18F-FDG-PET UTILITY IN MULTIPLE MYELOMA. NEW DURIESALMON PLUS STAGING SYSTEM. OUR EXPERIENCE I. Garcia, L. Entrena, C. Ramos-Font, A. Rodriguez-Fernandez (Hospital Universitario Virgen de la Nieves, Granada, Spain) |
| 0962 | AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN 5 PATIENTS AFFECTED BY POEMS SYNDROME L. Laurenti, S. De Matteis, P. Chiusolo, N. Piccirillo, F. Sorà, M. Tarnani, E. Rossi, T. Za, C. Giannotta, E. Nobile Orazio, G. Leone, S. Sica (Institute of Haematology, Rome, Italy) |
| 0963 | AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN 5 PATIENTS AFFECTED BY POEMS SYNDROME L. Laurenti, S. De Matteis, P. Chiusolo, N. Piccirillo, F. Sorà, M. Tarnani, E. Rossi, T. Za, C. Giannotta, E. Nobile Orazio, G. Leone, S. Sica (Institute of Haematology, Rome, Italy) |
| 0964 | SERUM DKK1 IN SMOLDERING MULTIPLE MYELOMA M. Hernandez-Martin, R.M. Fisac Herrero, C. Olivier Cornacchia, P. Tajada, M.J. Moro, R. Cuello, A. Martin Garcia-Sancho, C. Aguilera, J. Garcia-Frade, L. Lopez, T. Casadomartin, J.F. San Miguel (Hospital General de Segovia, Segovia, Spain) |
| 0965 | ELEVETED SERUM B-LYMPHOCYTE STIMULATOR (BLYS) LEVELS IN DIAGNOSIS ARE RELATED TO DISEASE AGGRESSIVENESS AND ADVERSE SURVIVAL IN MULTIPLE MYELOMA D. Maltezas, T. Tzenou, X. Papanikolaou, E. Koulieris, V. Bartzis, A. Gasiamis, T. Iliakis, T.P. Vasilakopoulos, P. Repousis, M. Dimou, G. Georgiou, M.K. Angelopoulou, M. Kotsopoulou, C. Mitsouli - Mentzikof, P. Panayiotidis, G.A. Pangalis, M-C. Kyrtsonis (Hematological Clinic, Metaxa Anticancer Hospital, Piraeus, Greece) |
| 0966 | EPIDEMIOLOGY OF BISPHOSPHONATE USE AND JAW OSTEONECROSIS INCIDENCE IN MULTIPLE MYELOMA PATIENTS IN THE REPUBLIC OF IRELAND J. McHugh, R.S. Kumar, A. O'Dalaigh, K. Breen, M. McCloy, R. Rajpal, A. Burke, M. Kelly, R. Desmond, C. O'Rafferty, P. Hayden, M. Leahy (Mid Western Regional Hospital, Limerick, Ireland) |
| 0967 | THE ASSOCIATION BETWEEN RESVERATROL WITH SIMVASTATIN DECREASES IGM SECRETION IN WALDENSTROM MACROGLOBULINAEMIA F. Iuliano (U.O di Oncoematologia, Rossano, Italy) |
| 0968 | THE CLINICAL SIGNIFICANCE OF TIMP-, TIMP-, MMP-, MMP-, OSTEOPROTEGERIN, SRANKL, AND ISS IN MULTIPLE MYELOMA PATIENTS L.C. Oliveira, J.A. Uzielli, M.S. Baggio, A.P. Lange, J.E. Tanus-Santos, E.M. Rego (Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil) |
| 0969 | EVALUATING THE POTENTIAL USE OF RISK CATEGORISATION IN THE MANAGEMENT OF MGUS M. Almeshhedani, A. Salamat, S. Al-Ismail (Singleton Hospital/ Swansea University, Swansea, United Kingdom) |
NON-HODGKIN LYMPHOMA - CLINICAL III
| 0970 | EFFICATIOUS BUT INSIDIOUS. A RETROSPECTIVE ANALYSIS OFFLUDARABINE-INDUCED MYELOTOXICITY USING LONG-TERM CULTURES -INITIATING CELLS IN 100 FOLLICULAR LYMPHOMA PATIENTS |
|---|---|
| 1971 | IN MANTLE CELL LYMPHOMA (MCL) THE MCL-INTERNATIONALPROGNOSTIC INDEX (MIPI) IS A BETTER PREDICTOR OFEVENT-FREE AND OVERALL SURVIVAL THAN INTERNATIONALPROGNOSTIC INDEX (IPI) IN PATIENTS RECEIVING INTENSIVE1ST LINE TREATMENT INCLUDING ASCT |
| 0973 | TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDY |
| 0974 | TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA:SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDY |
| 0975 | PHARMACOKINETICS OF RITUXIMAB AND THE DEVELOPMENTOF ANTIBODIES AGAINST RITUXIMAB IN PATIENTS WITH AB-CELL CD20+ MALIGNANCY L. Tran, A.D.R. Huitema, L. Aarden, J.H. Beijnen, J.W. Baars (Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands) |
| 0976 | POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER: REDUCTION OF IMMUNOSUPPRESSION AS INITIAL THERAPY. RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND PROGNOSTIC VARIABLES R. Reshef, S. Vardhanabhuti, M.R. Luskin, D.F. Heitjan, E.A. Stadtmauer, D.E. Tsai (University of Pennsylvania, Philadelphia, USA) |
| 0977 | SERUM B2-MICROGLOBULIN LEVELS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PROGNOSTIC SIGNIFICANCE UNDER TREATMENT WITH RITUXIMAB-CHOP (R-CHOP) T.P. Vassilakopoulos, A. Anastasopoulou, N. Constantinou, M.K. Angelopoulou, E. Stavroulaki, C. Kalpadakis, S. Sachanas, V. Pappis, P. Tsirkinidis, M. Moschoyiannis, O. Tsopra, T. Tzenou, A. Gassiamis, X. Yiakoumis,M.C. Kyrtsonis, S.I. Kokoris, M.P. Siakantaris, M. Dimou, G. Georgiou,E. Plata, N.A. Viniou, E. Variamis, K. Konstantopoulos, P. Panayiotidis,H. Papadaki, G.A. Pangalis (Department of Haematology, University of Athens, Athens, Greece) |
| 0978 | LENALIDOMIDE ORAL MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM AN INTERNATIONAL STUDY (NHL-003) P.L. Zinzani, C.B. Reeder, T.E. Witzig, J.M. Vose, R. Buckstein, C. Haioun, R. Bouabdallah, J. Polikoff, D. Pietronigro, M.S. Czuczman (Institute of Hematology and Medical Oncology “L. & A. Seràgnoli”, Bologna, Italy) |
| 1979 | IMPACT OF TIME-DEPENDENT VARIABLES ON THE OUTCOME OF SPLENIC MARGINAL ZONE LYMPHOMA: A DYNAMIC MODEL ON 84 PATIENTS S.R. Rattotti, L.A. Arcaini, C.P. Pascutto, F. Passamonti, M. Merli, S. Rizzi, M. Lucioni, E. Boveri, E. Rumi, C. Astori, M. Paulli, M. Lazzarino (Fondazione IRCCS Policlinico San Matteo - Università degli Studi, Pavia, Italy) |
| 0980 | RITUXIMAB PLUS CVP (CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISOLONE) COMBINATION CHEMOTHERAPY IN ADVANCED STAGE MARGINAL ZONE B-CELL LYMPHOMA AS A FIRST-LINE THERAPY B.Y. Ryoo, C. Suh, W.S. Kim, J.S. Kim, J.J. Lee, D.H. Yang, H.J. Kang, S.J. Kim, S.R. Lee, G.W. Lee, H.J. Kim, H.Y. Kim, S.Y. Oh, H. Kim, H.S. Eom,J. Chung, J. Park, Y.M. Park, J.S. Park (Korea Cancer Center Hospital, Seoul, South-Korea) |
| 0981 | MANTLE CELL INTERNATIONAL PROGNOSTIC INDEX (MIPI) AND BIOLOGICAL-MIPI ARE BETTER PREDICTORS OF THE OUTCOME OF MANTLE CELL LYMPHOMA (MCL) PATIENTS THAN IPI: A RETROSPECTIVE ANALYSIS A. Chiappella, C. Frairia, B. Puccini, B. Botto, L. Arcaini, E. Audisio, I. Baldi, G. Benevolo, C. Boccomini, A. Fabbri, R. Freilone, F. Marmont, L. Orsucci, P. Pregno, L. Rigacci, U. Vitolo (Hematology 2 AOU San Giovanni Battista, Turin, Italy) |
| 0982 | PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGEB- CELL LYMPHOMA TREATED WITH ORAL LENALIDOMIDE MONOTHERAPY: RESULTS FROM THE INTERNATIONAL STUDY NHL-003 C. Haioun, M.S. Czuczman, J.M. Vose, P.L. Zinzani, C.B. Reeder, R. Buckstein, R. Bouabdallah, J. Polikoff, A. Ervin-Haynes, T.E. Witzig (Hôpital Henri Mondor, Créteil, France) |
| 0983 | SURVIVAL IMPACT OF RITUXIMAB COMBINED TO ACVBP (R-ACVBP) IN 209 POOR RISK DLBCL NHL PATIENTS TREATED WITH UPFRONT HIGH-DOSE CONSOLIDATIVE AUTOTRANSPLANTATION (HDC): A GELA PHASE II STUDY O. Fitoussi, N. Mounier, K. Belhadj, H. Tilly, C. Haioun, O. Casasnovas, C. Ferme, J. Briere, B. Coiffier, P. Feugier, C. Gisselbrecht (Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France) |
| 0984 | CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN LYMPHOMAS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: A MULTICENTRICPROSPECTIVE ITALIAN STUDY G. Benevolo, P. Pioltelli, B. Botto, A. Stacchini, A. Evangelista, M. Spina, F. Mannelli, M. Cantonetti, A. Di Rocco, D. Pietrasanta, V. Pavone, N. Di Renzo, A. Ferreri, M.G. Cabras, U. Vitolo, E. Pogliani (Hematology, Turin, Italy) |
| 0985 | EFFICACY AND SAFETY OF LOW-INTENSITY ORAL AND INTRAVENOUS FLUDARABINE-CYCLOPHOSPHAMYDE WITH AND WITHOUT RITUXIMAB FOR FIRST-LINE TREATMENT OF FOLLICULAR LYMPHOMA A. Marin-Niebla, E. Rios-Herranz, J.F. Falantes Gonzalez, P. Cerezuela, M.L. Martino Galiana, R. Parody Ruiz-Berdejo, A. Urbano-Ispizua (Hospital Universitario Virgen del Rocio, Seville, Spain) |
| 0986 | A NEW SHORT-TERM HIGH INTENSIVE PROTOCOL BL-M-04 FOR ADULT PATIENTS WITH BURKITT LYMPHOMA: EFFICACY AND TOXICITY E. Baryakh, E. Zvonkov, S. Kravchenko, A. Kremenetskaja, A. Magomedova, T. Obukhova, A. Vorobjov (National Hematology Research Center, Moscow, Russian Federation) |
| 0987 | RETROSPECTIVE AND PROSPECTIVE ANALYSIS ON THE IMPACT OF HEPATITIS VIRUSES ON CHRONIC LYMPHOPROLIFERATIVE DISORDERS A.M. Vladareanu, C. Ciufu, M. Onisai, H. Bumbea, D. Cisleanu, I. Voican, C. Marinescu, D. Vasile, L. Barsan, A. Nicolescu, M. Dervesteanu, S. Radesi, C. Posea, A.M. Vintilescu, A. Ichim, C. Baluta, O. Cazaceanu, C. Savlovschi, C. Dobrea, C. Ardelean, V. Arama, V. Molagic, A. Streinu-Cercel, S. Arama, S. Costoiu, A. Rafila (Universitary Emergency Hospital Bucharest, Bucharest, Romania) |
NON-HODGKIN LYMPHOMA - CLINICAL IV
| 0988 | METHOTREXATE RELATED LYMPHOPROLIFERATIVE DISORDER -EXPERIENCE OF A DISTRICT GENERAL HOSPITAL IN THE UK |
|---|---|
| 0989 | CHLORAMBUCIL WITH OR WITHOUT RITUXIMAB IS AN EFFECTIVE THERAPY IN NON-GASTRIC MALT LYMPHOMAS |
| 0990 | REVIEW OF THE USE OF GDCVP (GEMCITABINE, DACARBAZINE, CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISOLONE )COMBINATION CHEMOTHERAPY IN RELAPSED/ REFRACTORY LYMPHOMA IN A LARGE UK HAEMATOLOGY AND BONE MARROW TRANSPLANT CENTRE |
| 0991 | VALUE OF 18F-FDG PET/CT FOR THE STAGING OF NON-HODGKIN´S LYMPHOMA: SIGNIFICANT IMPROVEMENT IN THE DETECTION OF NODAL AND EXTRANODAL LESIONS BUT MARGINAL IMPACT ON DISEASE STAGE |
| 0992 | FRONT-LINE AUTOLOGOUS PURGED TRANSPLANTATION IN INDOLENT NON-HODGKIN'S LYMPHOMAS: A LONG-TERM FOLLOW-UP STUDY M.T. Hernandez, B.J. González, P. Machado, M. Tapia, M.J. Rodríguez- Salazar, G. González-Brito, R.F. Rodríguez, J.V. Govantes, L. Morabito, J.M. Raya, S. Lakhwani, T. Martín, I. Gómez, M. Fernández, L. Hernández- Nieto (Hospital Universitario de Canarias, La Laguna. S/C de Tenerife, Spain) |
| 0993 | FRONT-LINE RISK-ADAPTED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN INTERMEDIATE/HIGH-RISK PATIENTS WITH FOLLICULAR LYMPHOMA V. Prochazka, T. Papajik, Z. Kubova, S. Rozmanova, M. Jarosova, K. Indrak (Teaching Hospital in Olomouc, Olomouc, Czech Republic) |
| 0994 | THE PROGNOSTIC SIGNIFICANCE OF THE NUMBER OF EXTRANODAL INVOLVEMENT SITES IN THE PATIENTS WITH DISSEMINATED DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP C. Yoo, B.S. Sohn, J.E. Kim, D.H. Yoon, S. Kim, D.H. Lee, S.W. Kim, C. Suh (Asan Medical Center, Seoul, South-Korea) |
| 0995 | ADDITION OF YTTRIUM-90 IBRITUMOMAB TIUXETAN TO BEAM CONDITIONING PRIOR TO AUTOGRAFTING DOES NOT IMPROVE OUTCOME OF CHEMOREFRACTORY PATIENTS WITH AGGRESSIVE B-CELL NHL I. Aurer, D. Huic, D. Nemet, Z. Mitrovic, M. Zuvic, R. Serventi-Seiwerth, D. Sertic, M. Mrsic, S. Basic-Kinda, I. Radman, B. Labar (University Hospital Center Rebro, Zagreb, Croatia) |
| 0996 | A POSSIBLE ROLE OF 18F-FDG PET SCANNING IN THE EARLY DETECTION OF RITUXIMAB-INDUCED PNEUMONITIS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA L. Nieuwenhuizen, F.J. Verzijlbergen, E Wiltink, J.C. Grutters, D.H. Biesma (Sint Antonius Hospital, Nieuwegein, The Netherlands) |
| 0997 | FIRST-LINE TREATMENT WITH RITUXIMAB AND BENDAMUSTINE IN OLD PATIENTS (80 YEARS AND OLDER) WITH AGGRESSIVEB-CELL LYMPHOMAS - AN INTERIM ANALYSIS OF AN ONGOINGPHASE II STUDY E. Weidmann, F. Fauth, A. Atmaca, S.E. Al-Batran, A. Neumann, C. Pauligk, E. Jager (Krankenhaus Nordwest, Frankfurt, Germany) |
| 0998 | KI-67 EXPRESSION IS PREDICTIVE OF PROGNOSIS IN PATIENTS OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RITUXIMAB PLUS CHOP C. Suh, D.H. Yoon, B.S. Sohn, J.E. Kim, C.H. Yoo, S. Kim, D.H. Lee, J.R. Huh (Asan Medical Center, University of Ulsan College of Medicine, Seoul, South-Korea) |
| 0999 | OCULAR ADNEXA NON HODGKIN LYMPHOMAS: A SINGLE CENTRE RETROSPECTIVE STUDY OF CLINICOPATHOLOGIC FEATURES, TREATMENT AND CLINICAL OUTCOME T. Perrone, F. Gaudio, S. Guerriero, A. Gentile, A. Giordano, A. Spina, F. Laddaga, V. Pavone, A. Guarini, C. Sborgia, G. Specchia, V. Liso, C. de Risi (Hematology, Bari University, Bari, Italy) |
| 1000 | EFFICACY AND TREATMENT COMPLIANCE OF DOSE-DENSE R-CHOP-14 IMMUNOCHEMOTHERAPY PLUS PEGFILGRASTIM FOR FIRST-LINE TREATMENT OF PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN OPEN-LABEL CLINICAL TRIAL IN SPAIN E. Gonzalez Barca, A. Salar, A. Oriol, M.J. Vidal, M. Canales, J. Bargay, S. Gardella, J. Briones, F.J. Tomas, S. Ferrer, D. Caballero (Institut Catalá d'Oncología, Barcelona, Spain) |
| 1001 | NEW VERTEBRAL FRACTURES IN NON-HODGKIN-LYMPHOMA (NHL) PATIENTS TREATED WITH CHEMOTHERAPY AND HIGH DOSE STEROIDS ARE RELATED TO THE INITIAL VALUES OF BONE MINERAL DENSITY (BMD) M.P. Bianchi, M.C. Cox, F. Conti, M. Pietravalle, A. Proietti, L. Vismara,V. David, C. Tatarelli, B. Veggia, G. Antolino, F. Mendicino, R. Camilli, P. Cardelli, B. Monarca, M.A. Aloe Spiriti (A.O.Sant'Andrea-II Faculty of Medicine-La Sapienza-Roma, Rome, Italy) |
| 1002 | HAEMATOPATHOLOGY DIAGNOSTIC SKILLS ACQUIRED IN A VIRTUAL LABORATORY: PRACTICAL TEACHING IN THE 21ST CENTURY JM O’Connor, C Burton, J Blase, W Curson, J Doughty, T Lightfoot, A Jack (St James's Institute of Oncology, Leeds, United Kingdom) |
| 1003 | IMMUNOHISTOCHEMICAL DETECTION OF ZAP-70 IN A SERIES OF MARGINAL ZONE LYMPHOMA (MZL) PATIENTS C. Kalpadakis, G.A. Pangalis, P. Korkolopoulou, T.P. Vassilakopoulos, G. Levidou, M.C. Kyrtsonis, S. Sachanas, X. Yiakoumis, E.M. Dimitriadou, F.N. Kontopidou, M.P. Siakantaris, E. Patsouris, P. Panayiotidis, H. Papadaki, M.K. Angelopoulou (Department of Haematology, University of Crete, Athens, Greece) |
| 1004 | OUTCOME OF AGGRESSIVE ATL-HTLV1 PATIENTS AFTER CHOP21 AS FIRST LINE TREATMENT - BUCHAREST EXPERIENCE D. Cisleanu, A.M. Vladareanu, H. Bumbea, S. Radesi, I. Voican, C. Ciufu, C. Marinescu, M. Onisai, A. Nicolescu, M. Dervesteanu, C. Dobrea, V. Popov, D. Colita, D. Mut-Popescu (Universitary Emergency Hospital Bucharest, Bucharest, Romania) |
| 1005 | INTENSIFIED CHOP (ICHOP) +/- RITUXIMAB IN PRIMARY MEDIASTINAL DIFFUSE LARGE B CELL LYMPHOMA (PMBCL): THE ROLE OF DOXORUBICIN/ CYCLOPHOSPHAMIDE DOSE-INTENSITY R. Mazza, M. Spina, M. Magagnoli, M. Demarco, L. Siracusano, L. Castagna, L. Giordano, U. Tirelli, A. Santoro, M. Balzarotti (Istituto Clinico Humanitas, Rozzano, Italy) |
THROMBOSIS AND VASCULAR BIOLOGY II
| 1006 | SUBCLINICAL ATHEROSCLEROSIS IN YOUNG B-THALASSEMIA |
|---|---|
| 1007 | SILICA CLOTTING TIME IN LABORATORY DIAGNOSIS OF LUPUS ANTICOAGULANT (LA). AN USEFUL TOOL FOR DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME (APS) IN PATIENTS ON ANTICOAGULANT TREATMENT |
| 1008 | POTENTIAL FUNCTION OF EGF1 DOMAIN PEPTIDE IN |
| 1009 | RELATIONSHIP BETWEEN INR MEASURED WITH DIFFERENT THROMBOPLASTINS, COAGULATION FACTOR LEVELS AND THROMBIN GENERATION IN PATIENTS RECEIVING ORAL VITAMINK ANTAGONISTS |
| 1010 | ENDOTHELIAL KLF4 LINKS PRO-INFLAMMATORY LEVELS TO THE EXPRESSION OF PAI-1 AND VWF GENE L.H. Yang (The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China) |
| 1011 | THE ANTITHROMBOTIC AND BLEEDING EFFECTS OF DABIGATRAN, A DIRECT THROMBIN INHIBITOR, AS COMPARED TO ENOXAPARIN, HEPARIN AND WARFARIN IN RATS J. Van Ryn, I. Kuritsch, M. Kink-Eiband, H. Priepke, W. Wienen (Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany |
| 1013 | GENETIC VARIABILITY OF FIBRINOGEN A-CHAIN GENE DEFINES FIBRINOGEN LEVELS BETWEEN HEALTHY INDIVIDUALS AND PATIENTS WITH DOCUMENTED ATHEROSCLEROSIS: EFFECTS ON PROTHROMBOTIC PROFILE I. Bossinakou, M. Kozanitou, N. Papageorgiou, A. Vlachopoulou, D. Tousoulis, E. Andronopoulou, M. Tsekoura M, C Stefanadis C, E Bossinakou (Hippocratio General Hospital, Athens, Greece) |
| 1014 | THE IMPACT OF THE GENETIC POLYMORPHISM G455A OF FIBRINOGEN B-CHAIN GENE ON FIBRINOGEN LEVELS, LOW-GRADE INFLAMMATORY PROCESS AND ENDOTHELIAL FUNCTION IN PATIENTS WITH ADVANCED ATHEROSCLEROSIS I. Bossinakou, N. Papageorgiou, M. Kozanitou, D. Tousoulis, Z. Pallantza, A. Vlachopoulou, M. Tsekoura M, C Stefanadis C, E Bossinakou (Hippocratio General Hospital, Athens, Greece) |
| 1015 | A NORMAL D-DIMER VALUE, MEASURED BY A HIGH SENSITIVITY ASSAY, RULE OUT A SUSPECTED VENOUS THROMBOEMBOLISM EPISODE INDEPENDENTLY OF PRETEST CLINICAL PROBABILITY J. Casals-Sole, D. Bernaudo, J. Camp, N. Lozano, E. Ballester, G. Escolar (Hospital Clinic, Barcelona, Spain) |
| 1016 | ELEVATED LEVELS AND DIFFERENT SUBSETS OF PROCOAGULANT MICROPARTICLES IN BREAST CANCER PATIENTS USING HORMONAL THERAPY M.C. Trappenburg, M. van Schilfgaarde, H.M. Spronk, H. ten Cate, A. Leyte, W.E. Terpstra (Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands) |
| 1017 | ROLE OF JAK2 MUTATION IN PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS: AIIMS EXPERIENCE S. Rathi, S. Sazawal, B. Sharma, T. Seth, A. Saraya, R. Saxena (AIIMS, Delhi, India) |
| 1018 | A TWO YEAR OBSERVATIONAL STUDY OF PATIENTS ATTENDING A DEEP VEIN THROMBOSIS CLINIC-DEMOGRAPHICS, RISK FACTORS AND ANATOMICAL SITE OF THROMBOSIS J. Blundell, J. McClure, A. McSorley (Royal Cornwall hospital, Truro, United Kingdom) |
| 1019 | THROMBOEMBOLISM PREDICTIVE FACTORS IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA A. Bellora, S. Tamiazzo, V. Primon, M. Pini, M.T. Corsetti, E. Cornaglia, M. Demichelis, R. Santi, L. Contino, A. Levis (SS Antonio and Biagio Hospital, Alessandria, Italy) |
| 1020 | JAK2 MUTATIONAL STATUS, HEMOSTATIC RISK FACTORS AND THROMBOPHILIC FACTORS IN ET PATIENTS B. Sokolowska, A. Nowaczynska, K. Bykowska, S. Chocholska, K. Wejksza, A. Walter-Croneck, M. Kandefer-Szerszen, T. Gromek, A. Kowalska, A. Dmoszynska (Medical University of Lublin, Poland, Lublin, Poland) |
| 1021 | ENDOTHELIAL CELLS (EC) AND ENDOTHELIAL PRECURSOR CELLS (EPC) KINETICS IN HAEMATOLOGICAL PATIENTS UNDERGOING CHEMOTHERAPY OR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) R. Pytlik, L. Kideryová, K. Bene_ová, R. Veselá, J. Karban, H. Rychtrmocová, M. Trnen_ (1st Medical Faculty, Charles University, Praha , Czech Republic) |
| 1022 | THE IMPACT OF THE GENETIC POLYMORPHISM G455A ON THE B-CHAIN FIBRINOGEN GENE ON THROMBOTIC PROCESS IN PATIENTS WITH CORONARY ARTERY DISEASE I. Bossinakou, M. Kozanitou, D. Tousoulis, N. Papageorgiou, E. Andronopoulou, M. Tsekoura M, C Stefanadis C, E Bossinakou (Hippocratio General Hospital, Athens, Greece) |
| 1023 | ASYMPTOMATIC BRAIN MAGNETIC RESONANCE IMAGING ABNORMALITIES IN ADULT PATIENTS WITH THALASSEMIAINTERMEDIA A. Taher, K. Musallam, W. Nasreddine, A. Inati, A. Beydoun (American University of Beirut Medical Center, Beirut, Lebanon) |
| 1024 | LOW LEVELS OF PROTEIN Z ARE ASSOCIATED WITH HELLP SYNDROME AND ITS SEVERITY I.K. Kaygusuz, T.F.T. Firatli Tuglular, T.T. Toptas, M.D. Demir (Marmara University, Istanbul, Turkey) |
| 1025 | MOLECULAR TYPING OF P. AERUGINOSA ISOLATES ALLOWS TO TRACE WATER AS THE SOURCE OF AN OUTBREAK OF MULTIRESISTANT PSEUDOMONAS BLOODSTREAM INFECTIONS C. Chiara, F. Bracchi, E. Casalone, E. Borlenghi, C. Barni, M. Gelmi, G. Ravizzola, F. Donnarumma, G. Mastromei, L. Baushi, N. Manca, L. Jacquot, G. Rossi (Spedali Civili, Brescia, Italy) |
| 1026 | CARDIAC BIOMARKERS AND ASSESSMENT OF CARDIAC TOXICITY DURING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES J.M. Horacek, L. Jebavy, M. Ulrychova, M. Tichy, P. Zak, J. Maly (University Hospital Hradec Kralove, Hradec Kralove, Czech Republic) |
| 1027 | SERIOUS EBV ENCEPHALITIS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) - SERIES OF 3 CASES M. Kouba, M. Markova, V. Valkova, M. Hricinova, P. Soukup, C. Salek, J. Mertova, J. Maaloufova, P. Hubacek, J. Cermak, A. Vitek, P. Cetkovsky (Institute of Haematology and Blood Transfusion, Prague, Czech Republic) |
| 1028 | MOLECULAR DIAGNOSIS APPROACH OF BLOOD STREAM INFECTIONS OF THE NEUTROPENIC PATIENT WITHHAEMATOLOGICAL MALIGNANCES V. Pavone, G. Lobreglio, G. Pasanisi, G. Maggio, M.C. Cosi, C. Zecca, C. Del Casale, A.R. Messa, S. Sibilla, A. Mele, R. Defrancesco (A.O. “Card. G. Panico”, Tricase (Lecce), Italy) |
| 1029 | THE ROLE OF PROPHYLACTIC ANTIMICROBIALS DURING AUTOLOGOUS STEM CELL TRANSPLANTATION : A SINGLE CENTER EXPERIENCE C. Suh, B.S. Sohn, D.H. Yoon, S. Kim, D.H. Lee, S.W. Kim, J.S. Lee (Asan Medical Center, University of Ulsan College of Medicine, Seoul, South-Korea) |
| 1031 | EFFECTIVENESS AND SECURITY OF ITRACONAZOL FOR INVASIVE FUNGAL INFECTION (IFI) PRIMARY PROPHYLAXIS IN PATIENTS WITH ACUTE LEUKEMIA C. Martinez, E. Lopez, I. Heras, A. Fernandez, M.L. Amigo, E. Perez, F.J. Ortuño, V. Vicente (Hospital Universitario Morales Meseguer, Murcia, Spain) |
| 1031 | PROGNOSTIC FACTORS AND OUTCOME OF PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT (ICU) WITH HEMATOLOGICAL MALIGNANCIES C. Martinez, E. Lopez, A. Carrillo, E. Perez, J.J. Sanchez, F. de Arriba, I. Heras, V. Vicente (Hospital Universitario Morales Meseguer, Murcia, Spain) |
| 1032 | COMPLIANCE TO IDSA-GUIDELINES FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ACUTE MYELOID LEUKEMIA M. Caira, A . Candoni, M. Offidani, B. Martino, M. Luppi, G. Specchia, C.G. Valentini, M.E. Tosti, F. Aversa, G. Leone, A. Nosari, L. Pagano (Catholic University, Rome, Italy) |
| 1033 | EFFICACY AND SAFETY OF MICAFUNGIN AS AN EMPIRICAL ANTIFUNGAL AGENT FOR FEBRILE NEUTROPENIC PATIENTS J.S. Park (Ajou University Hospital, Suwon, South-Korea) |
| 1034 | MOLECULAR DIAGNOSIS BY LIGHTCYCLER_ SEPTIFAST IN THE PREEMPTIVE TREATMENT OF INVASIVE FUNGAL INFECTIONS: A 5 CASES REPORT D. Clerici, N. Mancini, B. Forno, B. Cappelli, S. Mastaglio, C. Messina, A. Crotta, A. Assanelli, C. Corti, M. Bernardi, J. Peccatori, L. Fumagalli, F. Crippa, F. Ciceri, M. Clementi (San Raffaele Scientific Institute, Milan, Italy) |
| 1035 | MOLECULAR DIAGNOSIS OF BACTERIEMIA IN NEUTROPENIC FEBRILE ONCOHEMATOLOGICAL PATIENTS. PRELIMINARY RESULTS E. Gimeno, M.L. Sorli, E. Abella, A. Alvarez, J.P. Juan Pablo, M.T. Gimenez, A. Salar, B. Sanchez, C. Pedro, S. Saumell, C. Besses, M. Salvado (Hospital del Mar, Barcelona, Spain) |
| 1036 | RESPIRATORY SYNCYTIAL VIRUS INFECTION OUTBREAK IN CHILDREN WITH HEMATO-ONCOLOGICAL DISEASES A.U. Unuvar, S. Anak, D. Atay, Z. Karakas, G. Ozturk, T. Uzunhan, M. Garipardic, L. Agaoglu, O. Devecioglu (Istanbul University, Istanbul School of Medicine, Istanbul, Turkey) |
| 1037 | CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA IN HEMATOLOGY-ONCOLOGY PATIENTS S. Delimpasi (Evangelismos Hospital, Athens, Greece |
| 1038 | IN VITRO ANTIBIOTIC SYNERGY ON MULTIDRUG-RESISTANT STRAINS OF PSEUDOMONAS AERUGINOSA ISOLATED FROM ONCOHAEMATOLOGICAL PATIENTS G. Lobreglio, P. D'Aversa, M. Malagnino, L. Leo, M.J. Monteduro, L. Russo (A.O. “Card G Panico”, Tricase, Italy) |
| 1039 | IFN-GAMMA RELEASE ASSAY RESPONSES IN PATIENTS WITH CLINICAL SUSPICION FOR PULMONARY TUBERCULOSIS, AND IN HEALTH-CARE WORKERS WITH POTENTIAL FOR EXPOSURE TO M. TUBERCULOSIS G. Lobreglio, P. Barone, P. Errico, G. Maggio, M.C. Cosi, C. Zecca, G.C. Pasanisi (A.O. “Card G Panico”, Tricase, Italy) |
Print view ]
